Stockwinners Market Radar for September 08, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Cathie Wood's ARK Investment bought 25.4K shares of Nvidia today

19:05 EDT Trump Media Technology Group issues statement on Digital World Acquisition deal - Trump Media & Technology Group states: "The SEC has needlessly delayed its review of our proposed merger, causing real and unnecessary financial harm to DWAC investors, roughly 90% of whom are small, retail shareholders whom the SEC is chartered to protect. Despite its standard practice to provide comments within 30 days, the SEC has failed to give meaningful feedback on DWAC's registration statement for a stunning 115 days and counting. In the interests of simple fairness, the SEC needs to set aside any improper political considerations and bring its review to a swift conclusion."

18:12 EDT Juniper CEO sells $527K in common stock - In a regulatory filing, Juniper disclosed that its CEO Rami Rahim sold 18,750 shares of common stock on September 6th in a total transaction size of $527K.

17:20 EDT Corcept Therapeutics exec sells $1.3M in common stock - In a regulatory filing, Corcept Therapeutics disclosed that its Chief Business Officer Gary Robb sold 50K share of common stock on September 7th in a total transaction size of $1.3M.

17:16 EDT Teledyne awarded $596M contract to support ISS - Teledyne "announced that its subsidiary, Teledyne Brown Engineering, Inc., has been awarded the Marshall Operations, Systems, Services and Integration II contract. As the Prime Contractor, Teledyne is responsible for the management, personnel, supplies, and equipment to support mission operations and ground systems development services to support the International Space Station, ISS, and its missions."

17:13 EDT DocuSign jumps 17% to $67.90 after Q2 earnings beat and guidance

17:03 EDT Chevron granted interest in three carbon storage assessment permits - Chevron, through its affiliate Chevron Australia, is part of three joint ventures that have been granted an interest in three greenhouse gas assessment permits offshore Australia. The blocks, including two in the Carnarvon Basin off the north-western coast of Western Australia and one in the Bonaparte Basin offshore Northern Territory, total more than 31,500 km2 or nearly 7.8M acres - an area larger than Belgium. As part of its global lower carbon strategy, Chevron is focused on carbon capture, utilization, and storage, or CCUS, primarily through hubs with third-party emitters as partners and customers - renewable fuels, hydrogen, offsets, and other emerging technologies.

16:47 EDT Caterpillar reaches settlement with IRS - According to a regulatory filing, on September 8, 2022, Caterpillar reached a settlement with the U.S. Internal Revenue Service that resolves all issues for tax years 2007 through 2016, without any penalties. The company's settlement includes the resolution of disputed tax treatment of profits earned by Caterpillar SARL from certain parts transactions."We vigorously contested the IRS's application of the "substance-over-form" or "assignment-of-income" judicial doctrines and its proposed increases to tax and imposition of accuracy-related penalties," the company said. "The settlement does not include any increases to tax in the United States based on those judicial doctrines and does not include any penalties. The settlement is within the total amount of gross unrecognized tax benefits for uncertain tax positions and enables us to avoid the costs and burdens of further disputes with the IRS. We are subject to the continuous examination of our income tax returns by the IRS, and tax years subsequent to 2016 are not yet under examination."

16:30 EDT Halliburton completes sale of Russian operations - Halliburton Company announced it completed the sale of its Russia operations to a Russia-based management team made up of former Halliburton employees. As a result, Halliburton no longer conducts operations in Russia. The Russia-based management team now owns and operates Halliburton's former business and assets in Russia under the name BurService, which is independent from Halliburton.

16:25 EDT Pzena Investment reports preliminary AUM 47.5B as of August 31

16:23 EDT Sonoco Products unit, American Airlines Cargo enter partnership lease agreement - Sonoco ThermoSafe, a unit of Sonoco (SON), and American Airlines Cargo (AAL) announced a global partnership lease agreement for the new Pegasus ULD passive temperature-controlled bulk shipping container. The Sonoco ThermoSafe's Pegasus ULD will join the carrier's fleet of container products in the coming months. The Pegasus ULD is engineered with composite materials, offering a lighter solution that is also substantially more damage-resistant than traditional metal containers.

16:20 EDT Corporate Office Properties executes building lease in Huntsville, AL - Corporate Office Properties "executed a full-building lease with a defense contractor that is a Fortune 100 company at 1200 Redstone Gateway, a 121,000 square foot LEED Silver building in Huntsville, AL."

16:18 EDT VICI Properties raises quarterly dividend 8% to 39c per share - VICI Properties announced that its Board of Directors has declared a regular quarterly cash dividend of 39c per share of common stock for the period from July 1, 2022 to September 30, 2022, representing an annualized amount of $1.56 per share and an 8.3% increase from the current dividend rate. The dividend will be payable on October 6, 2022 to stockholders of record as of the close of business on September 22, 2022.

16:16 EDT Valaris announces $100M share repurchase program - The $100M authorization does not have a fixed expiration, and may be modified, suspended or discontinued at any time.

16:14 EDT 3D Systems forms new company Systemic Bio, invests $15M - 3D Systems announced the formation of a new, wholly owned company called Systemic Bio, a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. Systemic Bio will leverage 3D Systems' breakthrough, production-level bioprinting technology to create vascularized organ models using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with any desired drug compound to study drug metabolism and the effects on healthy or diseased tissue at the earliest stages of new pharmaceutical drug development. Systemic Bio's efforts will be supported by an initial $15M seed investment from 3D Systems, which, given the maturity of the underlying materials and process technology, is envisioned to support them through the start-up phase, bridging them to a material revenue level and profitability. To lead the new company, 3D Systems has named Taci Pereira as Systemic Bio's CEO. Pereira joined 3D Systems in May 2021 from Allevi, where she was chief scientific officer.

16:13 EDT Allied Esports Entertainment names Yinghua Chen as new CEO - Allied Esports Entertainment "announced that the Company's Board of Directors has appointed Yinghua Chen as Chief Executive Officer. Ms. Chen had previously served as the Company's President, Chief Investment Officer and Board Secretary. Given Ms. Chen's additional responsibilities, Ms. Chen will no longer serve the Company as Chief Investment Officer or Board Secretary, and will continue to serve as President. She has served as a director of the Company since 2020. Ms. Chen assumes the position of Chief Executive Officer from Lyle Berman, who has served as Co-Chairman of the Board and Interim Chief Executive Officer since February 2022. Mr. Berman retains his position as Co-Chairman of the Board, and has been appointed as Vice President, Mergers & Acquisition, where he will be more focused on the Company's M&A activities. As previously announced, the Company has engaged The Benchmark Company, LLC to serve as its exclusive financial advisor in connection with a potential business combination transaction. The Company has reviewed a number of potential target investment opportunities over the past several months, and due diligence, as well as the continued sourcing of other opportunities, remains ongoing. The Company also remains in the process of exploring strategic options for the Esports business. AESE intends to provide further updates in due course when appropriate."

16:11 EDT Simpson Manufacturing announces CEO retirement, succession plan - Simpson Manufacturing Co. announced that Karen Colonias will step down from her position as CEO as part of Simpson's succession plan, effective December 31. Simpson's board unanimously elected Michael Olosky, current COO, to succeed Karen Colonias as CEO, effective January 1, 2023, as part of a planned leadership succession. In connection with his promotion, Olosky will also join the company's board of directors on January 1, 2023. Colonias will continue in her role as CEO through the end of 2022, after which, as part of the succession plan, she will remain employed as an Executive Advisor to assist with the transition until her retirement on June 30, 2023.

16:08 EDT Limoneira still sees FY22 fresh lemon volumes 4.5M-5M cartons - The company's food service business and industry logistics continue to experience slowdown in its supply chain as well as inflationary pressures on a global basis. The company believes it will continue to experience improving year over year results for the fiscal fourth quarter of 2022 due to its stronger position in retail food and club grocery, as well as a gain from the joint venture with Lewis related to Harvest at Limoneira. The company continues to expect fresh lemon volumes to be in the range of 4.5 million to 5.0 million cartons for fiscal year 2022. For the first nine months of fiscal year 2022, the company achieved avocado volume of approximately 8.0 million pounds, which exceeds the expected range of 6.0 million to 7.0 million pounds for fiscal year 2022. The company expects cash distributions to be $95 million from Harvest at Limoneira during the next five fiscal years, beginning in fiscal year 2022.

16:04 EDT Kilroy Realty raises quarterly dividend 3.8% to 54c per share - Kilroy Realty Corporation announced that its board of directors declared a regular quarterly cash dividend of 54c per common share payable on October 12, 2022 to stockholders of record on September 30, 2022. The dividend is equivalent to an annual rate of $2.16 per share and is a 3.8% increase from the previous annualized dividend level of $2.08 per share.

16:02 EDT Aerojet Rocketdyne appoints Joseph Chontos as general counsel - Aerojet Rocketdyne announced that acting general counsel Joseph Chontos has been selected for promotion to VP and appointment as general counsel and corporate secretary on September 8. Chontos joined the company in 2018 as deputy general counsel and has served as acting general counsel since April. In his new role, he will manage all legal functions, including corporate, governance, litigation, employment, environmental, intellectual property, and other legal and regulatory compliance matters. The company's Ethics and International Trade Compliance functions also report to Legal.

15:37 EDT Coinbase says STX deposits and transactions are halted - "Investigating - STX deposits and withdrawals are halted," said the company. Reference Link

15:11 EDT FDA alerts providers about faulty MitraClip products from Abbott - The U.S. Food and Drug Administration said it is alerting health care providers about potential clip lock malfunctions with MitraClip Clip Delivery Systems manufactured by Abbott. On September 8, 2022, Abbott issued an Urgent Medical Device CorrectionExternal Link Disclaimer to inform health care providers about the issue. An increased rate of reports of clip lock malfunctions has been observed before and after clip deployment. These events appear to occur in approximately 1.3% of MitraClip procedures and have been observed with all device models. The potential risk to patients in the event of a clip lock malfunction includes ineffective treatment of mitral regurgitation and the potential need for additional interventions contributing to increased procedural risks such as bleeding, complications with implanting additional clips, and longer procedural times. The majority of reported clip lock malfunction events have not been associated with adverse patient outcomes. Based on the available data on clip lock malfunctions and the associated risks, the FDA believes that the probable benefits of the MitraClip device continue to outweigh the probable risks for the approved indications for use. The FDA is issuing this letter to ensure the public is aware of the manufacturer's recall notice and recommended actions. Reference Link

15:01 EDT Nikola President files to sell 19,973 shares - Nikola Motor President Michael Lohscheller, who has been named to succeed as CEO when Mark Russell retires, filed to sell 19,973 shares of company stock with a market value of $101,574.69, according to a regulatory filing. Reference Link

14:52 EDT Warner Bros. Discovery CFO 'wouldn't necessarily say' EBITDA view 'conservative' - Asked at the Bank of America Media, Communications and Entertainment conference if the company is "just being conservative" with its revised FY22 adjusted EBITDA view of $9.0B-$9.5B and its FY23 adjusted EBITDA guidance of "at least $12B," Warner Bros. Discovery CFO Gunnar Wiedenfels replied: "Well, I view that number as sort of a good balance target for next year. I wouldn't necessarily say it's conservative. I get your point if you take our synergy guidance, and I'm very confident in how that's ramping up. That gets you there. But I also don't want to be out here. It's very early still to talking about a full year of 2023, and I do want to reiterate that there's uncertainty in the macroeconomic environment, no question about it. So the puts and takes here are -- a very bad macro environment would certainly be a big headwind here. On the other hand, we might make a little more progress a little faster on the synergy side than what we're modeling right now. I view this as a good sort of bar for next year."

14:21 EDT Shopify promotes Nejatian to COO, appoints Hoffmeister as CFO - Shopify (SHOP) announced leadership changes. Kaz Nejatian, Vice President of Product, has been promoted to Chief Operating Officer, effective immediately. Nejatian succeeds Toby Shannan, who is retiring from his role at the company and is expected to join Shopify's Board of Directors, effective January 1, 2023. Shannan will serve as a special advisor through the end of the year. Nejatian will remain VP of Product while undertaking his new role. Jeff Hoffmeister, CPA, has been appointed Chief Financial Officer. He succeeds Amy Shapero, who is stepping down following the company's third quarter 2022 earnings announcement on October 27. Hoffmeister will join Shopify from Morgan Stanley (MS), where he spent over two decades in its Technology Investment Banking group. "Kaz is the right person to succeed Toby Shannan in the Chief Operating Officer role. Kaz is an innovative and strategic product leader who knows first hand what it means to make commerce better for everyone, which positions him ideally for this role. I would also like to thank Toby for his invaluable leadership and commitment to Shopify over the last decade. We look forward to continuing to benefit from his guidance as he transitions into his new role of special advisor and then Board member in 2023. As we position Shopify for the future, the addition of Jeff to our leadership team will continue to strengthen our ability to deliver value for our merchants, partners and investors. We are fortunate to benefit from his more than 20 years of investment banking experience in the technology sector, and his keen vision of the future of the industry," said Tobi Lutke, Founder and CEO of Shopify.

14:12 EDT Tandem Diabetes CEO saw 'positive shift,' start of 'momentum build' in August - Speaking at the Wells Fargo Healthcare conference, Tandem Diabetes CEO John Sheridan said: "Okay. Well, let me start off by saying that on the Q3 call, we indicated that we had pressure in June and July that we didn't anticipate. And I think that now that we've exited August, we've seen a positive shift in the beginning of a momentum build that really confirms our assumptions in the guidance for the second half of the year. So I wanted to just say that. I also want to say that we -- looking at the new starts, it's 50-50 MDI and competitive conversions, and we're seeing strong renewal update also. And so as we -- as you just mentioned, I mean, clearly, we factored COVID in. We've seen it for the last several quarters. We factored the competitive challenges in there. These things pretty much occurred as we had anticipated they would. There was no real surprise. I would say that the thing that did surprise us was the macro factors. And I think that it's interesting, since we have said that, a number of analysts have come out and said, yes, in fact, they have interviewed endos and endos said, yes, it is a meaningful problem that's affecting their patient population. And so it is real out there. I'll also just say that there's also been a question says, how do we know it's the macro factors versus the competition? And I'll just say that typically, the people who are affected by these macro issues are people have already decided to purchase a Tandem pump. They're in our funnel. They're talking to our internal sales organization. And in the conversations that we're having with these people, they're basically saying that they're just -- there's uncertainty and some doubt and there's -- they're pausing actually... And so there's definite knowledge that this is going on. It's not that the competitive environment has taken over. We have tangible evidence that this is what's going on." In afternoon trading while the company presents at the conference, Tandem Diabetes shares are up $4.80, or 10%, to $50.45.

13:55 EDT User reports indicate problems at Twitter, Downdetector says - Reference Link

13:38 EDT Golden Path Acquisition Corporation (Units) trading resumes

13:36 EDT FDA issues safety communication on reports of cancers around breast implants - The U.S. Food and Drug Administration is informing the public about reports of cancers, including squamous cell carcinoma, or SCC, and various lymphomas, in the scar tissue that forms around breast implants. The various lymphomas reported are not the same as the lymphomas described in previous FDA Communications as Breast Implant-Associated Anaplastic Large Cell Lymphoma, or BIA-ALCL, the agency stated. "The FDA learned about these reports through our continual postmarket review of breast implants and our ongoing collaboration with external stakeholders. After preliminary review of published literature as part of our ongoing monitoring of the safety of breast implants, the FDA is aware of less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant. As of September 1, 2022, the FDA has received 10 medical device reports about SCC related to breast implants and 12 MDRs about various lymphomas related to breast implants. The FDA recognizes the limitations of MDR data, including that reports do not necessarily represent unique cases. Reports submitted to the FDA are just one source the FDA uses to monitor the safety of medical devices, in addition to mandated postmarket studies, published literature, and real-world data from registries and claims databases. The FDA will continue to gather and review all available data from these sources to evaluate the occurrence of cancers in the capsule around breast implants," the agency stated. Breast implant makers include Sientra (SIEN), Abbvie's (ABBV) Allergan unit and Johnson & Johnson (JNJ). Reference Link

12:02 EDT Stewart appoints John Hamm as CIO - Stewart Information Services Corporation announced that John Hamm has been hired as the new Chief Information Officer for its global technology operations, overseeing and leading the company's technology development and strategy. Current CIO Brad Rable has been promoted to President, Technology and Operations. Prior to joining Stewart, Hamm served as Vice President of Information Technology at Texas Children's Hospital.

12:00 EDT Innovid falls -14.1% - Innovid is down -14.1%, or -52c to $3.16.

12:00 EDT Kenon rises 13.3% - Kenon is up 13.3%, or $4.62 to $39.47.

12:00 EDT Asana rises 28.1% - Asana is up 28.1%, or $5.35 to $24.39.

11:32 EDT Regeneron, Sanofi present Phase 3 PRIME trial results of Dupixent - Detailed results from the Phase 3 PRIME trial evaluating Dupixent in adults with uncontrolled prurigo nodularis were presented today in a late-breaking session at the European Academy of Dermatology and Venereology 2022 Congress. These data from one of two pivotal trials in prurigo nodularis show Dupixent significantly reduced itch and skin lesions at 24 weeks. In total, 22 scientific abstracts are being presented at the EADV 2022 Congress discussing Dupixent in atopic dermatitis in patients as young as six months, and its investigational use in chronic spontaneous urticaria and bullous pemphigoid, in addition to prurigo nodularis. The late-breaking data presented at the EADV 2022 Congress are from the randomized, placebo-controlled Phase 3 PRIME trial, which met its primary and key secondary endpoints. At 24 weeks, among patients treated with Dupixent in the trial: More than three times as many (60%) experienced a clinically meaningful reduction in itch from baseline, the primary endpoint, compared to placebo patients. Nearly three times as many achieved clear or almost clear skin, a key secondary endpoint, compared to placebo patients. The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indication. For the 24-week treatment period, overall rates of adverse events were 71% for Dupixent and 63% for placebo. AEs most commonly observed with Dupixent included nasopharyngitis and headache The rate of treatment discontinuation due to AEs prior to week 24 was 0% for Dupixent compared to 4% for placebo. A numerically lower rate of skin infections was observed with Dupixent. Results from this and an earlier Phase 3 trial, PRIME2, will form the basis of regulatory submissions around the world for Dupixent in prurigo nodularis this year. Regulatory submissions are already under review by the European Commission and the U.S. Food and Drug Administration, with the FDA granting Priority Review in May 2022 and a target action date of September 30, 2022. The potential uses of Dupilumab in prurigo nodularis, chronic spontaneous urticaria and bullous pemphigoid are currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

11:03 EDT BetMGM, Arizona Cardinals debut first sportsbook at NFL stadium - BetMGM and the Arizona Cardinals debuted the first sportsbook at a National Football League stadium. The BetMGM Sportsbook at State Farm Stadium is a two-story, 17,000-square-foot entertainment destination featuring state-of-the-art sports wagering amenities, concert-hosting facilities, a gourmet grille and bar and a variety of screens to watch games.

10:52 EDT Corning sees Q3 coming in at bottom end of sales, EPS guidance - The company cites lower volume in display. Previous guidance was for core EPS of 51c-55c and sales of $3.65B-$3.85B. Consensus is currently 53c and $3.74B, respectively. Comments taken from Citi Global Technology Conference.

10:11 EDT Cinedigm partners with Katch to integrate Genomic Data into Cineverse - Cinedigm announced that the Company is partnering with Katch to integrate its unique Genomic Data into Cinedigm's forthcoming, flagship streaming service, Cineverse. The company said, "Much like how Pandora changed the way millions of people discover music, Cineverse will be among the first to enhance content discovery by utilizing an extensive metadata classification system to categorize film and television series via Katch's proprietary set of Universal Genomic Traits that account for tone, character arcs, mood, context and thematic nature, among many other qualitative traits."

10:08 EDT Applied DNA, CUCVM enter research collaboration for LinearDNA platform - Applied DNA Sciences and the Cornell University College of Veterinary Medicine announced the signing of a research agreement to advance LinearDNA-based vaccine research and discovery for animal diseases with agricultural biosecurity implications. Primarily, the Agreement seeks to combine LinearDNA as a platform for rapid drug development with CUCVM's expertise in viral vector design to advance a differentiated approach to animal vaccine development for infectious diseases.

10:05 EDT WWE appoints Dan Ventrelle as EVP, talent, Maurice Edelson as CLO - WWE announced that Dan Ventrelle will join the company as EVP, Talent, and Maurice Edelson will join as EVP, Chief Legal Officer. Ventrelle was most recently with the NFL's Las Vegas Raiders, where he served as the team's President. As EVP, Talent, Ventrelle will oversee the company's talent department and report to Chief Content Officer Paul Levesque. Edelson joins the company from The Juilliard School, where he served as General Counsel since 2015. As Chief Legal Officer, Edelson will report to Chairwoman & co-CEO Stephanie McMahon.

10:01 EDT Cummins announces $5M partnership investment with Reinventure Capital - Cummins announced a $5M partnership investment with Boston-based Reinventure Capital, an impact fund that invests in U.S. based companies led and managed by people of color and/or womxn. Co-founded and managed by expert impact investor, Edward Dugger, III, Reinventure provides its partners the opportunity to advance racial and gender equity through access to diversified portfolio companies while achieving competitive returns.

10:00 EDT American Eagle falls -11.6% - American Eagle is down -11.6%, or -$1.34 to $10.25.

10:00 EDT Kenon rises 13.3% - Kenon is up 13.3%, or $4.62 to $39.47.

10:00 EDT Asana rises 22.1% - Asana is up 22.1%, or $4.21 to $23.25.

09:51 EDT Shuttle Pharmaceuticals Inc trading resumes

09:50 EDT Net Element trading resumes

09:49 EDT Rivian, Mercedes-Benz seek joint venture for van manufacturing in Europe - Mercedes-Benz Vans and Rivian (RIVN) announced the signing of a memorandum of understanding to initiate a strategic partnership. The partnership will enable the companies to cooperate on the production of electric vans. Subject to the parties entering into final binding agreements and to obtaining the relevant regulatory clearances, the companies intend to establish a new joint venture manufacturing company with the purpose of investing in, and operating, a factory in Europe to produce large electric vans for both Mercedes-Benz Vans and Rivian, starting in a few years. The target is to build an all-new electric-only production facility leveraging an existing Mercedes-Benz site in Central/Eastern Europe. They will aim to produce two large vans, one based on VAN.EA, MB Vans Electric Architecture, the electric-only platform of Mercedes-Benz Vans, and the other based on the second generation electric-van, Rivian Light Van platform. "Further options for increased synergies from the joint venture will also be explored," the companies said in a statement. Shares of Rivian Automotive are up 9% to $36.39 in morning trading.

09:47 EDT Torrid falls -12.8% - Torrid is down -12.8%, or -69c to $4.68.

09:47 EDT Kenon rises 13.6% - Kenon is up 13.6%, or $4.75 to $39.60.

09:47 EDT Asana rises 18.5% - Asana is up 18.5%, or $3.52 to $22.56.

09:39 EDT InMed Pharmaceuticals Inc trading resumes

09:37 EDT Coinbase funding suit challenging Treasury's Tornado Cash sanctions - Coinbase says it is funding a lawsuit brought by six people challenging the U.S. Treasury Department's sanctions of the Tornado Cash smart contracts and is asking the court to remove them from the U.S. sanctions list. "The sanctions exceed Treasury's authority, harm innocent people, remove privacy and security options for crypto users, and stifle innovation," Coinbase wrote in a blog post. Tornado Cash is an open source piece of software running on the Ethereum blockchain that "preserves privacy by allowing users to deposit assets from one crypto address and withdraw them using a different crypto address," the company said. "We have no issue with the Treasury sanctioning bad actors and we take a hard stance against unlawful behavior. But in this case, Treasury went much further and took the unprecedented step of sanctioning an entire technology instead of specific individuals," it added. Reference Link

09:35 EDT Aetna to enter the ACA individual insurance exchange marketplace in some states - Aetna, a CVS Health company, is entering the individual insurance exchange marketplace in Delaware and in select counties in Illinois and New Jersey with its Aetna CVS Health co-branded insurance product

09:33 EDT ShiftPixy trading halted, volatility trading pause

09:33 EDT Nuvei announces selection by Arcadier as 'preferred payment partner' - Nuvei Corporation announces that it has been selected by Asia-based Arcadier as "its preferred payment partner" in the U.S., Latin America, Europe, the Middle East, and Africa. Commenting on the partnership, Nuvei President Yuval Ziv said: "Arcadier is a forward-focused technology company at the forefront of the latest marketplace trends. At Nuvei, we are trusted for our local and global payment solutions that are designed specifically to relieve merchants of the complexities inherent to multi-channel payments. We're delighted to support Acadier's push into new markets."

09:30 EDT Montage Gold announces government approval of Mankono exploration permits - Montage Gold announces that on September 6, 2022, the Ivorian Council of Ministers approved the award of the Gbongogo and Sisseple Exploration Permits to the Mankono-Sissedougou Joint Venture. This marks a critical step in the process towards closing of the previously announced acquisition of Mankono by Montage. Montage expects to close the Transaction in the coming weeks, following receipt of the signed Presidential decree in respect of the Gbongogo Exploration Permit. With the granting of the Mankono permits now approved, Montage is pleased to provide disclosure of the extensive historic database of results from Mankono for the first time, as well as details of the Company's exploration plans and strategy.

09:24 EDT Blink Charging stations to be deployed at UBS Asset Management properties - Blink Charging and UBS Asset Management's Real Estate & Private Markets business announced a mutual service agreement for the deployment of Blink charging stations and related services to UBS-owned properties throughout the U.S. This agreement allows UBS to select from Blink's business models to support the needs of each facility.

09:22 EDT Visionary Education Technology establishes Canadian Asian Cultural Foundation - Visionary Education Technology Holdings Group hosted a Gala Event in Toronto September 3rd to announce the establishment of the Canadian Asian Cultural Foundation. The Foundation's goals are to promote and maintain interest in traditional Asian culture and to support the rich Chinese heritage and promote Asian culture and education in Canada, while fostering the development of a diverse Canadian culture.

09:21 EDT Regeneron to resume trading at 9:50 am ET - Regeneron is set to resume trading at 9:50 am ET, with quotation scheduled to resume at 9:45 am ET, according to Nasdaq. The stock was halted for trading, pending news, before the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema, or DME, and wet age-related macular degeneration, or wAMD.

09:20 EDT Mullen Automotive acquires 60% interest in Bollinger Motors for $148.2M - Mullen Automotive announces its acquisition of a controlling interest in EV truck innovator Bollinger Motors. This is Mullen's first EV acquisition and propels the Company into the medium duty truck classes 3-6, along with the B1 and B2 sport utility trucks. The purchase price is $148.2 million in cash and stock for a 60% controlling interest, which gives Mullen the majority ownership of Bollinger Motors, Inc. and positions Bollinger to capture the electric sport utility and commercial vehicle markets. Launched in 2015, Bollinger Motors is an American automobile designer and manufacturer of electric sport utility and medium duty vehicle lines. The company also successfully developed proprietary vehicle battery packs, drivetrains, and thermal and vehicle control software units. In 2017, Bollinger built and debuted the critically acclaimed B1 class 3 sport utility vehicle, the first of its kind. The company followed its initial success with the development of the second-generation B1 and B2 vehicles, before pausing in favor of commercial truck development. With years of history in class 3 truck development, intellectual property, patents and expertise, the company's decision made sense to pivot into commercial vehicle development for classes 3-6. As part of the acquisition, the company brings Mullen nearly 50,000 reservations previously taken for the B1 and B2 sport utility vehicles. With Mullen's acquisition and capital injection, both B1 and B2 programs will begin after the start of production for class 3-6 commercial truck programs. The company brings a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets such as last mile delivery, refrigeration, utilities and their upfitters. On Sept. 1, 2022, Bollinger revealed for the first time the B4, a class 4 electric commercial truck. The B4 electric chassis cabs will be the first of the company's commercial lineup to hit the ground in upcoming client test programs. The new Bollinger B4 incorporates years of feedback from dozens of major fleets looking to electrify their vehicles. The result is a cab-forward truck, designed from the ground up to offer maximum cargo volume, accommodate unlimited adaptation and prioritize safety. Bollinger will be testing B4 chassis cab trucks this fall with numerous fleet customers, upfitters and charging companies to gather constructive feedback

09:19 EDT Hostess Brands announces partnership with NAMI - Hostess Brands announced a new partnership with the National Alliance on Mental Illness, NAMI, focusing its efforts on becoming a StigmaFree workplace and supporting NAMI's grassroots efforts to improve mental health resources in local communities where Hostess Brands operates. "At Hostess, our mission is to inspire moments of joy by putting our hearts into everything we do," said Andy Callahan, CEO of Hostess Brands. "As the company that is all about sparking joy, we recognize that mental and emotional well-being is essential to happiness. It is critical to us that we demonstrate the importance of employee mental health and prioritize a StigmaFree workplace. We are excited about our national partnership with NAMI and the opportunity we have to do our part to make joy possible in the communities we serve by creating awareness, reducing stigma and increasing belonging."

09:17 EDT Westhaven Gold announces drill results from Shovelnose gold property - Westhaven Gold announced drill results from its ongoing drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt 30 km south of Merritt, British Columbia. Highlights include: in the FMN Zone: 1.84 g/t gold and 4.79 g/t silver over 21.90 meters and 3.90m of 4.33 g/t Au and 9.61 g/t Ag starting 62m downhole; 30.58m of 1.06 g/t Au and 4.09 g/t Ag; 0.60m of 3.11 g/t Au and 287.00 g/t Ag, and 1.13m of 2.31 g/t Au and 173.44 g/t Ag. Current drilling continues to expand the main mineralized structure along strike to the northwest. Discovery of a new gold bearing zone situated 1.2 km northeast of the South Zone: 3.28 g/t Au over 0.9m; 1.39 g/t Au over 1.2m and another 1.23 g/t Au over 6m. Westhaven has drilled approximately 31,000m in 108 holes at Shovelnose in 2022. Drilling on peripheral targets off the main northwest trending 4km-long gold-bearing structure hosting Vein Zone 1 has encountered a new subparallel vein zone at the Hydrothermal Breccia No. 2 target. At the Shovelnose gold property, the primary focus of Westhaven's 2022 drilling is to test the potential for additional gold and silver mineralization along the 4km 'main mineralized' structure hosting the South, Tower, FMN and Franz Zones. However, a component of the 2022 work program is designed to evaluate geological, geochemical and geophysical targets elsewhere on the 17,623ha property.

09:16 EDT Maxeon Solar CEO Waters to step down, CRO Babcock appointed interim CEO - Maxeon Solar Technologies announced that the Company's board of directors and Chief Executive Officer, CEO Jeff Waters have agreed that Waters will step down as CEO and member of the Board effective September 15, 2022, and that Maxeon's Chief Revenue Officer, CRO, Mark Babcock has been appointed interim CEO effective September 15, 2022. The Board has retained an outside firm to conduct a search process for the new CEO.

09:15 EDT Abbott announces three-year data on impact of Amplatzer Piccolo Occluder - Abbott announced three-year data showing the positive impact of the Amplatzer Piccolo Occluder on treating babies with a potentially life-threatening hole in the heart known as a patent ductus arteriosus, PDA. The Amplatzer Piccolo device is smaller than a pea and is the world's first and only minimally invasive, transcatheter treatment approved to close a PDA in premature infants with this common congenital heart defect. The latest data were presented at the Pediatric and Congenital Interventional Cardiovascular Society Symposium, held in Chicago from September 7-10, 2022. Three-Year Results from the Amplatzer Piccolo Study: The ADO II AS trial showed the safety and effectiveness of the Amplatzer Piccolo device in closing PDAs in premature babies, with data through three years showing: High survival rate, with no procedure-related deaths; High implant success rate and complete PDA closure in nearly all patients; Low device-related serious adverse event rate with no late device-related events. "The Amplatzer Piccolo Occluder is a lifesaving device for premature infants with PDAs, many of whom require urgent treatment to survive but aren't responding to medical management and are at high risk for surgery," said Evan Zahn, M.D., director of the Guerin Family Congenital Heart Program in the Smidt Heart Institute and Department of Pediatrics at Cedars-Sinai Medical Center, and principal investigator of the ADO II AS trial. "The data from this study reinforce Piccolo's ability to safely and effectively treat this life-threatening heart problem for our tiniest patients."

09:14 EDT Sage Group to integrate Sage Accounting with Square POS - Sage and Square announce a new partnership, focused on helping small businesses work smarter and save time, freeing them up to grow their businesses. The partnership allows Sage Accounting and Square's point of sale software to integrate, and it is now live in Canada, the UK and Ireland. It means customers using both products can do business and take payments anywhere - in-person, online or over the phone. Sales data then flows seamlessly into Sage Accounting, keeping retailers' books up-to-date and accurate.

09:12 EDT PagerDuty names Sesh Tirumala as CIO, Heather Hinton CISO - PagerDuty announced the appointments of Sesh Tirumala as Chief Information Officer and Heather Hinton as Chief Information Security Officer. With these appointments, the company bolsters its technical leadership at the executive level as it continues to expand its investment in operational excellence, platform resilience, security, and scalability. With more than 25 years of experience in technology leadership roles at Anaplan and Cisco , Tirumala will help PagerDuty to improve operational efficiency, create data-driven, seamless relationships with customers, and streamline employee experience. He has extensive experience leading teams responsible for strategy, architecture, acquisitions, technology product delivery, and shared services.

09:11 EDT First Citizens' CIT provides $10M to Blue Sky Specialty Pharmacy - CIT, a division of First Citizens Bank, announced that its Asset-Based Lending business provided $10M in financing to Blue Sky Specialty Pharmacy. The financing was arranged via a collaboration between First Citizens Middle Market Banking team and the Asset-Based Lending and Healthcare Finance businesses that First Citizens acquired in January through its merger with CIT. "Blue Sky's innovative business model and people-first approach helps them stand out in the specialty pharmacy industry," said Chris Esposito, managing director and group head for CIT's Asset-Based Lending business. "We were pleased to assist them in arranging this financing and look forward to future opportunities to support their business goals."

09:10 EDT Match Group names Williams as Chief People Officer - Match Group (MTCH) announced the appointment of D.V. Williams as Chief People Officer, CPO, effective Tuesday, September 13. In his new role, Williams will oversee people operations, including compensation; benefits; people information systems; diversity, equity, and inclusion; and learning & development for Match Group and its global portfolio of brands. He will be based in Los Angeles and report to Match Group Chief Executive Officer Bernard Kim. Williams joins Match Group from Cars.com (CARS), where as Chief People Officer he led all aspects of human resources and diversity, equity, and inclusion. "D.V. is an exceptional people leader whose expertise in talent retention and recruitment will be an enormous asset as we pursue our innovation goals," said Bernard Kim, CEO of Match Group. "We're thrilled to welcome D.V. to the Match Group family, and we can't wait to see how he'll make the workplace experience even richer for our employees."

09:10 EDT Net Element trading halted, news pending

09:09 EDT Volcon launches Volcon Brat class 2 e-bike - Volcon announced that it has officially entered into the e-bike market with the launch of its class 2 e-bike, the Volcon Brat. The Brat has been built with four ride modes to accommodate everything from off-road adventures to maneuvering through urban traffic with ease. These modes vary from minimal pedal assist to full throttle engagement. With 70+ miles of riding fun on a single charge in Mode 1, the Brat provides enough range to empower your adventure and get you back home. The Brat is powered by a 48V battery that can be fully charged in 6-7 hours via Level 1 charging through a standard household outlet. Volcon expects to begin delivering the Brat to dealers and consumers in November 2022, with an MSRP starting at $2,799.

09:08 EDT Verisk Analytics selected by Aurenity for risk insight and pricing solutions - Verisk's underwriting and rating solutions have been selected by Aurenity, a new managing general agent in the excess and surplus ) insurance market. Aurenity plans to launch its initial excess casualty product in Q3. Aurenity has used a variety of Verisk products and services to help develop its platform.

09:06 EDT Motorsport Games plans to effect 1-for-10 reverse stock split - The Company also announced that its Board of Directors approved a reverse split of its Class A and Class B common stock at a 1-for-10 split ratio. Pursuant to the Support Agreement, Motorsport Network agreed to vote all of its shares of Class A and Class B common stock, representing approximately 94% of the combined voting power of the Company's Class A and Class B common stock, in favor of the reverse stock split and in favor of any required actions related to such reverse stock split. With Motorsport Network's agreement to provide its approval, the Company will have adequate shareholder support to approve the split at the special meeting of stockholders.

09:06 EDT Sintx Technologies reports on FDA pre-submission meeting for spine implants - Sintx Technologies has held a 'successful' 510(k) pre-submission meeting with the FDA concerning the potential development and commercialization of silicon nitride-PEEK spine implants. In the meeting, FDA officials provided supportive feedback related to the company's underlying regulatory assumptions and strategies. Sintx intends to utilize the FDA's guidance to move forward with 510(k) filing and initiate commercialization efforts to introduce spine implants made of its novel FleX-SN PEEK composite material. To create FleX-SN PEEK, Sintx partnered with Solvay, a provider of materials, chemicals, and solutions, to enhance their Zeniva PEEK biomaterial. The resultant FleX-SN PEEK product is expected to facilitate faster bone healing, improve radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection. Sintx submitted a Master Access File for FleX-SN PEEK to the FDA in early 2021.

09:06 EDT Motorsport Games announces restructuring program - Motorsport Games announced several important steps forward in strengthening the Company's business, capital structure and foundation for achieving future growth. First, the Company executed a Support Agreement with its majority stockholder, Motorsport Network, pursuant to which Motorsport Network recently paid a $3 million cash advance to Motorsport Games under the terms of the parties' pre-existing line of credit. Second, the Company announced a new organizational restructuring program that is expected to generate material annualized cost reductions of approximately $4 million by the end of 2023. The goal of the 2022 Restructuring Program is to build a stronger global business operation, enhance the Company's cost efficiency and improve the Company's operating margins. In an effort to re-gain compliance with NASDAQ's continued listing standards, the Company also announced its plans to effect a 1-for-10 reverse stock split during the fourth quarter of 2022, following stockholder approval. Motorsport Network agreed to exercise its combined 94% voting power to support the reverse stock split at a special meeting expected to be held shortly. The 2022 Restructuring Program is designed to reduce the Company's marketing, general and administrative expenses, improve the Company's profit and Adjusted EBITDA and maximize efficiency, cash flow and liquidity. Through the 2022 Restructuring Program, the Company expects to eliminate approximately 20% of its overhead costs worldwide, including budgeted open positions, and deliver approximately $4 million of total annualized cost reductions by the end of 2023. The immediate headcount cost reductions are expected to deliver annualized cost reductions of approximately $2.5 million by the end of 2022, with additional actions to be taken during 2022 expected to generate an additional $1.5 million of annualized cost reductions by the end of 2023. The 2022 Restructuring Program includes right-sizing the organization and operating with more efficient workflows and processes. The primary components of the organizational restructuring involve consolidating certain functions; reducing layers of management, where appropriate, to increase accountability and effectiveness; and streamlining support functions to reflect the new organizational structure. The leaner organizational structure is also expected to improve communication flow and cross-functional collaboration, leveraging the more efficient business processes. In addition, given the ongoing uncertain economic environment and the potential effect that it could have on net sales, this action will also provide the Company with additional flexibility. In connection with implementing the 2022 Restructuring Program, the Company expects to recognize during 2022 approximately $0.1 million to $0.3 million of total pre-tax restructuring and related charges, consisting primarily of employee-related costs, such as severance, retention and other contractual termination benefits. The Company expects that substantially all of these restructuring charges will be paid in cash during 2022, with the balance, if any, expected to be paid in 2023. The amounts and timing of all estimates are subject to change until finalized and may vary materially based on various factors.

09:04 EDT BAE Systems receives $13M contract for advanced GPS for U.S. F-15E aircraft - BAE Systems has received a $13M contract for advanced Global Positioning System GPS technology to protect U.S. F-15E aircraft from GPS signal jamming and spoofing. The company's Digital GPS Anti-jam Receiver, DIGAR, will ensure the reliability of military GPS systems for aircraft operating in challenging signal environments. "Modern airborne missions require accurate positioning and navigation data, and GPS systems must be able to withstand adversaries' best disruption efforts," said Greg Wild, Navigation and Sensor Systems product line director at BAE Systems. "Our DIGAR antenna electronics are trusted to protect these platforms in contested environments."

09:04 EDT Regeneron says primary endpoints met in two pivotal trials of aflibercept 8 mg

09:02 EDT Arcimoto FUVs available to rent at Hyatt Place Eugene/Oakway Center - Arcimoto and Hyatt Place Eugene/Oakway Center announced that Arcimoto Fun Utility Vehicles are now available for guests to rent directly at the hotel.

08:55 EDT Regeneron trading halted, news pending

08:46 EDT Forward Air names Nancee Ronning chief commercial officer - Forward Air announced that Nancee Ronning has accepted the role of chief commercial officer and will join the company's leadership team at the end of September. Ronning brings a track record of growth from GE Capital, Merrill Corporation and BNSF Logistics to Forward. She will be responsible for Forward's commercial strategy and organic growth across all Forward businesses.

08:45 EDT Siyata Mobile launches CrisisGo Panic App integration - Siyata Mobile announced that its SD7 rugged mission-critical push-to-talk device is now integrated with CrisisGo's Panic App, giving teachers instant access to first responders with a single push of a button. Integrated SoS communication improves response times and public safety during times of school community crisis.

08:41 EDT II-VI changes name to Coherent, launches new brand identity - II-VI (IIVI) announced a corporate name change to Coherent (COHR) and a new brand identity, following the completion of II-VI's acquisition of Coherent on July 1. The new brand identity includes a new corporate logo representing the atom. The organization will maintain II-VI's founding date of 1971 and its founding place and corporate headquarters as Saxonburg, Pennsylvania. The pre-merger companies' existing websites, social media platforms, and most product branding will continue for the near term as the transition to the new brand identity is executed over the coming months.

08:40 EDT Future FinTech signs MOU to acquire Alpha International Securities - Future FinTech announced that on September 1, 2022, Future FinTech Limited, a wholly owned subsidiary of the Company, signed a Memorandum of Understanding for Equity Acquisition, MOU, to acquire Alpha International Securities from Alpha Financial Limited. The purchase price and acquisition terms of the acquisition are to be determined pending due diligence and a financial audit of Alpha Securities by FTFT HK, with a formal acquisition agreement to be executed within 60 days after the parties are satisfied with the results of the due diligence and a mutual agreement as to the terms of the acquisition. Shanchun Huang, Chief Executive Officer of Future FinTech, commented, "We believe that this potential acquisition will be synergistic with Nice Talent Asset Management Limited, our 90%-owned asset management subsidiary also based in Hong Kong, as well as other financial services businesses that we are developing. We believe that Alpha Securities could also play an important role in our continued transformation as we internationalize and diversify our business and income flows. Our objective is to become a diversified fintech enterprise that optimizes current opportunities and integrates them into a comprehensive and strategic business platform."

08:38 EDT SharpLink Gaming to acquire SportsHub Games Network in all-stock deal - SharpLink Gaming entered into an Agreement and Plan of Merger pursuant to which it will acquire 100% of SportsHub Games Network in an all-stock transaction. Closing of the acquisition is subject to the satisfaction of certain closing conditions, including shareholder approval by SharpLink's shareholders. Founded in 2015 by a team of veteran fantasy sports industry insiders, SportsHub operates a variety of real-money fantasy sports and sports simulation games on its fully-licensed platform. The platform reaches more than 2 million fantasy sports fans who spend almost $40 million annually on its portfolio of games and contests, helping the Company generate nearly $6 million in annual revenues in 2021. SportsHub's platform currently includes: National Fantasy Championships, the premier operator of high stakes fantasy football, baseball and basketball contests with grand prize payouts as high as $250,000 and featuring the industry's premier live draft experience in Las Vegas and New York; Bestball10s, the hugely popular season-long best ball league format; Fanball, one of the top daily fantasy sports destinations where users compete against similarly skilled players in draft, auction and salary cap style daily fantasy sports contests; Fantasy National Golf Club, a provider of world class data analysis and research tools for fantasy golf players and sports bettors; WhatIfSports, one of the leading sports simulation sites featuring online simulation games and predictions for MLB, NFL, NHL, NBA, NCAA sports and more; and LeagueSafe, an online platform for private fantasy leagues to collect entry fees, provide transparency into league transactions, secure funds throughout the season, encourage timely payment of entry fees, and facilitate end-of-season payouts. LeagueSafe is the trusted source for collecting and protecting private fantasy league dues since 2008 and attracts over 150,000 paying users each year. The proposed acquisition of SportsHub is key to SharpLink's plan to accelerate and amplify its audience growth initiatives. By leveraging the SportsHub platform, the acquisition would enable SharpLink to have a proven "plug and play" solution to easily onboard potential future acquisitions in an efficient and scalable way. SportsHub is currently SharpLink's largest shareholder, holding approximately 8.9 million shares of SharpLink's Ordinary Shares. Pursuant to the terms and conditions of the merger agreement, SBET will be required to distribute such shares to its stockholders effective as of immediately prior to the closing of the merger. Upon the closing of the merger, the stockholders of SportsHub will receive an aggregate of 3.67 million ordinary shares of SharpLink in exchange for all outstanding capital stock of SportsHub. All of the approximately 12.6 million SharpLink Ordinary Shares to be distributed or issued to the stockholders of SportsHub pursuant to the share distribution and the merger, as applicable, will be subject to a six-month lock-up period; thereafter, a percentage of the holder's shares may be eligible for resale each month until no restriction exists

08:37 EDT Scynexis presents positive interim data of ibrexafungerp for candida infection - Scynexis presented positive interim data in patients with refractory candidiasis treated with oral ibrexafungerp from the ongoing Phase 3 FURI study, as well as data from the ongoing CARES study of patients with Candida auris infections. In the study, 56% of patients had a complete or partial response, 27% had stable response, 9% showed disease progression, and 8% were indeterminate. Among these patients, 71% of refractory vulvovaginal candidiasis cases - 10/14 - treated with an investigational dose regimen of ibrexafungerp showed clinical improvement as determined by vulvovaginal signs and symptoms score less than or equal to at test of cure, 7% had stable response, 14% showed disease progression, and 7% were indeterminate. Of the 18 patients with invasive candidiasis/candidemia due to C. auris, 78% had a complete or partial response, 11% had stable response, one patient died of other causes, and one outcome was indeterminate.

08:35 EDT Cryoport enters strategic relationship with Takeda's BioLife Plasma - Cryoport (CYRX) announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda (TAK), intended to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. By bringing together BioLife Plasma Services' proficiency in apheresis collection and their donation center infrastructure with Cryoport's life sciences' world-class capabilities and expertise in temperature-controlled supply chain solutions for the biopharmaceutical industry, the companies aim to establish a standardized, integrated apheresis collection, processing, and distribution solution for cellular therapies. Importantly, the new platform will leverage the cryo-processing expertise of Cell Matters, which Cryoport acquired in late July 2022. Commenting on the agreement, Jerrell Shelton, Chief Executive Officer of Cryoport stated, "This strategic relationship with BioLife Plasma Services is a prime example of how our world-class expertise in providing supply chain solutions to the life sciences industry and our expansion into new geographies and services offerings, such as bioservices and cryo-processing, creates exciting new opportunities. Our goal is to streamline the complex processes necessary to treat an increasing number of patients with today's most advanced cell therapies while ensuring the highest quality and safety standards."

08:35 EDT Sono Motors plans to present Sion to U.S. audience in Q4 - As key milestones in 2022, Sono Motors will debut four B2B-customer projects, including CHEREAU, Kogel, Wingliner, and Mitsubishi Heavy Industries Thermal Transport Europe at the end of September at IAA Transportation, the leading trade fair for the transportation industry. On top the Company plans to present the Sion for the first time ever to an U.S. audience in the fourth quarter 2022. In terms of financial guidance for 2022, Sono Motors expects to generate further revenues with solar customers, the vast majority of which are expected for the fourth quarter of 2022.

08:35 EDT Exela Technologies adds new customer ClearBank to XBP Platform - Exela Technologies announced a new customer, ClearBank, an enabler of secure accounts, real-time clearing and embedded banking for financial institutions. Exela will provide its XBP platform and processing services, enabling connectivity to Pay.UK's interbank Image Clearing System. XBP is the largest revenue generator in the ITPS line of business, which generated $874.2M in FY 2021. The Pay.UK Image Clearing System will enable ClearBank to extend its agency banking services by adding an enhanced cheque processing solution to multiple banks and financial institutions.

08:33 EDT The Very Good Food Company announces review of strategic alternatives - The Very Good Food Company announced that it has initiated a process to evaluate potential strategic alternatives to maximize shareholder value, which could include the acquisition by, or a merger with, an industry partner involving all or part of VERY GOOD's business or assets. While the strategic review process is ongoing, the Company will remain focused on the successful implementation of its three-prong approach to Stabilize, Right-Size, and Optimize, first announced in May 2022, to maintain and enhance the value of VERY GOOD's business and operations. There can be no assurance that the strategic review process will result in any strategic alternative, or any assurance as to its outcome or timing.

08:32 EDT Simtek Corporation appoints Prue as Chief Accounting Officer - SmartKem announced the new appointment of Nigel Prue as Chief Accounting Officer. Nigel has extensive experience implementing SOX compliance procedures and prior to joining SmartKem in 2021 worked as Director of Finance at Global Eagle Entertainment.

08:29 EDT DMG Blockchain Solutions expects modest change in Q4 realized hashrate - The company said, "In the current quarter, this situation has worsened with summer temperatures, and as such, we expect only a very modest change in realized hashrate in the quarter to end September 30, 2022. DMG expects the situation to markedly improve in the December quarter as temperatures rapidly cool and we approach our expected calendar year end target of 1 EH/s of installed mining capacity, assuming Bitmain deliveries and installations stay on track."

08:27 EDT Xperi announces details for completion of separation - Xperi announced that its board of directors has approved the details and timing of the previously announced spin-off of the company's product business, Xperi Inc. from the company's IP licensing business, Adeia. The board has declared a distribution of the then issued and outstanding shares of common stock, par value $0.001 per share, of Xperi Inc. as a dividend on a pro rata basis to the company's stockholders of record as of the close of business on Wednesday, September 21. Each company stockholder of record on the record date will receive a distribution of four shares of Xperi Inc. Common Stock for every ten shares of common stock, par value $0.001 per share, of the company, that it holds on the record date. Each company stockholder of record on the record date will receive cash in lieu of the fractional shares of Xperi Inc. Common Stock created as a result of the spin-off. The spin-off is expected to occur on or about October 1. Upon completion of the spin-off, Xperi Inc. will be an independent, publicly traded company, and the company will retain no ownership interest in Xperi Inc. It is anticipated that "when-issued" trading in Xperi Inc. common stock on the NYSE will begin on or about September 20, under the symbol "XPER WI," and that Xperi Inc. common stock will begin "regular-way" trading on the NYSE on October 3 under the symbol "XPER". The company will be renamed Adeia Inc. and is expected to remain trading on the Nasdaq under the new stock symbol "ADEA".

08:26 EDT Eli Lilly announces new data on Phase 3 study on lebrikizumab - New detailed results from Eli Lilly and Company's Phase 3 monotherapy studies in atopic dermatitis, AD, showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response at Week 16 through one year of treatment. Lebrikizumab, a high-affinity and potent IL-13 inhibitor, delivered similar results when dosed once every four weeks or once every two weeks after Week 16. These data were featured in a late-breaking, oral presentation at the 31st European Academy of Dermatology and Venerology Congress. The company previously announced topline results of these one-year analyses of ADvocate 1 and ADvocate 2 in June 2022. "Despite available treatment options, many patients with atopic dermatitis experience distressing symptoms every day over the course of years. Thus, there is a clear need for new therapies that maintain long-term results," said Andrew Blauvelt, M.D., board-certified dermatologist, president of Oregon Medical Research Center and lead author of the ADvocate analyses. "Lebrikizumab helped patients reduce the impact of atopic dermatitis by maintaining long-lasting skin clearance and itch relief with dosing at every four weeks in the ADvocate studies. These data help deepen our understanding of the role lebrikizumab may play in treating atopic dermatitis and will assist practitioners to improve clinical outcomes for their patients with this chronic disease."

08:25 EDT Amgen announces new data at EADV 2022 for Otezla - Amge announced results from two significant Phase 3 clinical studies of oral Otezla, demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology, EADV, Congress, taking place in Milan, Italy, Sept. 7-10, 2022. SPROUT study in pediatric moderate to severe plaque psoriasis: The SPROUT study investigated the efficacy and safety of Otezla in pediatric patients aged 6 to 17 years with moderate to severe plaque psoriasis inadequately controlled by or intolerant to topical therapy. The primary endpoint of the static Physician's Global Assessment response at week 16 was met with a 33.1% sPGA response for Otezla versus 11.5% for placebo. The major secondary endpoint was also met: a greater proportion of patients achieving a 75% or more reduction in the Psoriasis Area and Severity Index score, with 45.4% for Otezla versus 16.1% for placebo. The adverse events were consistent with the known safety profile of Otezla. DISCREET study in moderate to severe genital psoriasis: 16-week data from the DISCREET study in adult patients with moderate to severe genital psoriasis, demonstrated a clinically meaningful and statistically significant improvement in genital psoriasis, with twice as many patients achieving the primary endpoint of a clear or almost clear score on the Physician Global Assessment of Genitalia scale when receiving Otezla, when compared with placebo. The secondary endpoints of the study were also met. The data showed improvements in sPGA response, with 21.5% responding for Otezla versus 7.2% for placebo, and Genital Psoriasis Itch Numeric Rating Scale response, at 46.0% for Otezla versus 19.6% for placebo. Additionally, data showed greater reduction in affected body surface area, with a 4.12% mean reduction with Otezla versus 0.79% with placebo; a Dermatology Life Quality Index burden score reduction of 5.3 for Otezla versus 2.6 for placebo; a Genital Psoriasis Symptoms Scale reduction in mean score of 20.5 for Otezla versus 5.3 for placebo; and a reported improvement in sexual health impacted by psoriasis with Otezla. The adverse events were consistent with the known safety profile of Otezla, with the most commonly reported in either treatment group being diarrhea, headache, nausea and nasopharyngitis.

08:24 EDT Seagate partnering with Catalog in DNA-based storage and computation platforms - Seagate is collaborating with Catalog Technologies, a provider of automated DNA-based digital data storage and computation, on several initiatives to advance scalable and automated DNA-based storage and computation platforms, including making DNA-based platforms up to 1000 times smaller. The collaboration will center on using Seagate's "lab on a chip" technology to reduce the volume of chemistry required for DNA-based storage and computation. Using the Seagate platform, tiny droplets of synthetic DNA can test chemistry at significantly smaller levels. This research aims to provide valuable insights into possibilities for the next generation of DNA-based storage and computation platforms in various form factors, including desktop and IoT-sized versions. The goals for the next-generation platform are to use significantly smaller amounts of chemicals, require less energy, and operate almost anywhere-including in offices, on ships in the middle of the ocean, and potentially in space.

08:21 EDT Reliance Global entered into referral partnership with NRS Funding - Reliance Global (RELI) has entered into a referral partnership with NRS Funding, a service of National Retail Solutions and a provider of merchant cash advance services to independent retailers nationwide. Under the agreement, RELI Exchange affiliated agents will now be able to offer clients merchant cash advance services. NRS operates a point-of-sale terminal-based platform for independent retailers nationwide, including convenience, grocery, liquor, and tobacco stores. NRS is a subsidiary of IDT (IDT).

08:19 EDT 3M HIS division secures federal government clearance for platform IT, security - The 3M Health Information Systems, 3M HIS, division has achieved fully authorized Federal Risk and Authorization Management Program, FedRAMP, status for its 3M RevCycle health services platform, RHSP. 3M HIS is the company's first division with a FedRAMP-approved product. With this designation, 3M RHSP is published on the FedRAMP marketplace, allowing federal entities to more easily contract and work with the company. "We duplicated our commercial Health Services Platform to operate through Amazon GovCloud to achieve a fully authorized FedRAMP status," said Kim Aiello, 3M HIS director of federal market solutions. "I am extremely proud of our federal markets team for achieving a FedRAMP ATO, which provides our platform with enhanced visibility, opens the door for us to secure cloud-hosted contracts with federal organizations, and makes it easier for us to add more products and solutions that are cybersecure and government approved."

08:19 EDT Nokia selected by Stealth Communications for core network upgrade - Nokia has been selected by Stealth Communications to upgrade the New York City-based internet service provider's metro core network throughout this high-density metropolitan area. Nokia's IP routing solutions will be deployed to build a core router mesh network for increased capacity and scale. Stealth Communications provides connectivity services to customers in finance, real estate, education, and government through its 80-mile fiber-optic system that connects hundreds of commercial office buildings. To increase capacity and scale within its network and ensure reliability, Stealth is investing in its metro core by implementing 400GE connectivity. Nokia will also work with Stealth Communications to extend the provider's IP core network to bring 100GE connectivity to its multi-tenant buildings. tealth Communications has also selected the Nokia Deepfield Defender for protection against Distributed Denial of Service. Deepfield Defender provides a holistic perspective on DDoS attacks across the entire network as they happen.

08:15 EDT SeaChange and Source Digital partner for metaverse monetization - SeaChange has partnered with Source Digital, a provider of Source Activated Moments, a Web3 alternative that creates immersive and personalized user engagement across any video or digital metaverse experience. The new partnership provides an alternative to monetizing video and metaverse content, while aiming to activate the full potential of advertising inventory on connected TVs by building interactive moments that engage the user for increased clickthrough rates. The first commercial application of the partnership will be to deploy Source, a connected TV enabled network designed for consumers in the OTT and metaverse space, leveraging Source Activated Moments and SeaChange StreamVid platform, a software-as-service designed to allow content owners to publish, distribute and monetize all types of content across all device platforms, including connected TVs.

08:13 EDT Labrador Gold announces results from drilling at Kingsway project - Labrador Gold announced results from recent drilling targeting the prospective Appleton Fault Zone over a 12km strike length. The drilling is part of the Company's ongoing 100,000 metre diamond drilling program at its 100% owned Kingsway Project. Highlights of the drilling include an intersection of 2.02 g/t Au over 32 metres from 134 metres that included 18.08 g/t Au over 0.63 metres and 11.42 g/t Au over 1.05 metres in Hole K-22-177 from the north end of Big Vein. The intersection is approximately 75 metres north of the discovery outcrop. In addition, Hole K-22-187 at Big Vein southwest intersected 12.84 g/t Au over 0.8 metres from 341 metres. The last results from initial drilling at Midway showed an intersection of 5.69 g/t Au over 1.33 metres in Hole K-22-171. Further drilling is planned at Midway to test the continuity of gabbro-hosted mineralization along strike towards Cracker. "Drilling at Big Vein continues to deliver excellent results with the longest mineralized intersection of 32 metres grading 2.02 g/t gold drilled on the property to date. We are currently testing this intersection down dip. The intersection is approximately 30 metres north of another long intercept of 6.07 g/t Au over 19m in hole K-21-111." said Roger Moss, President and CEO. "Big Vein has now been drilled over a strike length of approximately 520 metres and remains open both to the northeast and southwest. Two rigs continue drilling at Big Vein to test for extensions of the mineralization in both directions."

08:11 EDT Nocera acquires 80% interest In Meixin Institutional Food for $4.3M - Nocera announced its acquisition of an 80% controlling interest in Meixin Institutional Food Development using Variable Interest Entity agreements VIE. The purchase price of the acquisition was $4.3M. Meixin, a well-established food processing and catering company established in 2003, is engaged in the production of hot and frozen meals, bento boxes, group meals and processing of vegetables and fruits for other companies in the food industry. Meixin has been catering and serving bento boxes to local banks and companies for the last 19 years, including Chinatrust Bank, Fubon Bang Bank, Eastern Kun, and Good Time Technology. As part of Nocera's vertical integration effort of turning its seafood into delicious and valuable meals, Meixin will produce different food products for Nocera to sell through its distribution channel including bento boxes, takeaway seafood porridge, BBQ eel rice, and seafood fried rice.

08:10 EDT Singing Machine announces sponsorship of Paretta Autosport - The Singing Machine Company announced that it will be a sponsor of the No. 16 Paretta Autosport Dallara Chevrolet for the upcoming Firestone Grand Prix of Monterey, on September 9th through September 11th.

08:08 EDT Katapult adds SimpleTire to partner network - Katapult has added SimpleTire, an online tire retailer, to its network of merchant partners. The partnership gives all SimpleTire customers - and particularly those with non-prime credit ratings who may not have access to traditional financing options - a way to obtain replacement tires. Other merchants that offer Katapult lease-purchase payment options include Wayfair, Lenovo and Purple Mattress.

08:07 EDT Exscientia announces Caroline Rowland as Chief People Officer - Exscientia announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia's People and Places functions and build on the Company's talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil. "Exscientia was founded to create an entirely new type of biopharma company, re-engineered to integrate technologists and drug discovery scientists who share a passion for using technology to make better medicines, faster. In recent years, we've expanded our global footprint rapidly, and ensuring that our unique culture persists as we scale is critical," said Andrew. "Caroline brings over 20 years of global experience in optimising organisational effectiveness and unlocking higher levels of company performance through operational growth and a sense of belonging. Caroline's expertise and guidance will be invaluable in helping Exscientia excel as a globally diverse and innovative organisation."

08:06 EDT Energy Vault signs SESS EPS contract with Wellhead Electric and W Power - Energy Vault announced the signing of the Stanton Energy Storage System, or SESS, EPC contract with Wellhead Electric and W Power, a woman-owned business enterprise that has developed and owned power generation facilities in California. The project will be operated by Wellhead Services, one of the most experienced developers and operators of innovative energy generation and energy storage facilities in California, which is based in Sacramento, California. Energy Vault will begin deployment immediately in 2022 of a 275.2 MWh battery storage project at W Power's Energy Reliability Center in Stanton, California. The project is on an accelerated timeline to meet critical power needs for southern California and is expected to be completed in mid-2023. Energy Vault will also support W Power and Wellhead with development and deployment of future energy storage projects in California representing approximately 600 MWh+ of additional capacity in the near term. The system will be built on Energy Vault Solutions', orEVS, proprietary integration platform and powered by EVS' energy management software. The EVS platform, which was introduced in Q4 2021, leverages the most advanced software architecture and optimization algorithms, and enables the integration and orchestration of multiple energy assets under a multitude of use cases. Together with the company's existing sustainable long duration gravity energy storage technology offering, Energy Vault continues to advance the global transition to a carbon-free, resilient power grid.

08:06 EDT Applied UV receives $1.5M purchase order for resort in Orlando - Applied UV announces that its wholly-owned subsidiary, MunnWorks, received a purchase order for approximately $1.5M for domestic production of furniture and mirrors for installation at a luxury resort located in Orlando, Florida. Max Munn, President and Director of Applied UV and MunnWorks, stated, "This order further validates our strategic decision to acquire domestic production to mitigate risks related to supply chain and import tariffs. Our domestic production capabilities were a key differentiator in securing this win. We are increasingly encouraged by the additional opportunities we are pursuing with a number of hotel operators for installations across the United States. We have a number of active projects in our recently acquired 100,000 square foot facility in the 'model room' phase with well-known, luxury hotel franchises that amount to approximately $8 million in incremental sales from new clients in the coming months, in addition to ordinary recurring sales."

08:04 EDT Bionano Genomics announces published study of OGM in stem cell evaluation - Bionano Genomics announced the publication of a study demonstrating the utility of optical genome mapping - OGM - as part of a workflow to evaluate the quality of hypoimmunogenic induced pluripotent stem cells - iPSCs - which could be used in regenerative medicine. This research provides scientific and practical support for OGM's ability to detect cryptic and balanced structural variants in CRISPR-edited cells. The expansion of iPSC-mediated cell therapy faces risks due to immune rejection. Researchers in this study developed a new strategy for the reduction of immune rejection using CRISPR-Cas9 genome editing. In the study, OGM matched the karyotype and genome sequencing findings of deletions and translocations and identified complicated genomic rearrangements missed by other methods. OGM was also able to detect distinctive mutations in iPSCs that researchers could then avoid using. Bionano offers OGM solutions for applications across basic, translational and clinical research.

08:03 EDT SPAR Group announces review of strategic alternatives - SPAR Group announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives to maximize shareholder value. As part of the process, the Board will consider a full range of strategic alternatives, including a sale, merger, divestiture, recapitalization, going private, other strategic transactions, or continuing to operate as a public, independent company. "With a strong balance sheet, 90%+ revenue growth over the last 5 years, increased profit margins, diversified services and long-term relationships with some of the most important consumer goods and retail companies in the world, we believe we are in the best financial and operational position in the company's history, yet our stock continues to trade well below a comparable industry value," said Mike Matacunas, President and CEO. "The management team is aligned with the Board that the best way to maximize shareholder value is to explore options that will unlock our potential and provide a platform for continued growth and success. Regardless of the process or outcome, the entire SPAR organization will remain committed to the execution of our work, growing our business, serving our clients and supporting our employees and joint venture partners." The Board has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurance that the review will result in any transaction or other strategic change or outcome. The Company does not intend to comment further until it determines that further disclosure is appropriate or necessary.

07:57 EDT Silvercorp Metals releases fiscal 2022 sustainability report - Silvercorp Metals announces the publishing of its annual Sustainability Report for Fiscal 2022, detailing the Company's commitment and contributions to environmental, social, and governance, ESG, factors, practices, and management, while delivering long-term value to shareholders. "At Silvercorp, we believe that sustainability is one of our fundamental responsibilities," said Dr. Rui Feng, Chairman and CEO of Silvercorp. "Silvercorp's core objectives are to operate safely, sustainably, and responsibly with the environment and collaboratively with local communities. While our approach to sustainability will continue to evolve over time, our commitment to integrating ESG factors in our strategic planning, operations, and management remains the same."

07:43 EDT Monarch Mining reports results from Swanson drilling program - Monarch Mining has received additional results from the 2021-2022 drilling program on its wholly-owned Swanson gold project, including more high-grade assays and wider mineralized zones. The Swanson property lies 50 kilometers north of Monarch's wholly owned 750 ton-per-day Beacon mill. The 2021-2022 program is the first drilling done on the property since Monarch Gold acquired it from Agnico-Eagle Mines in 2017. The positive results received to date have encouraged Monarch to continue testing the extensions of the gold mineralization along strike and at depth. The most recently received assay results are for six holes. The deepest, most easterly down-plunge hole, intersected multiple gold-bearing zones. The highest-grade interval within the corridor from the reported holes included segments of up to 7.83 g/t Au over 8.82 m. The mineralized corridor appears to widen at depth and includes an intersection grading an average of 0.99 g/t Au over 237.82 m. The highest-grade intersection from the reported down-dip holes included segments of 7.07 g/t Au over 1.95 m and 11.05 g/t Au over 1.0 m at vertical depths of 280 m and 320 m below surface. Drilling near surface to the west confirmed that the mineralization extends beyond the limit of the currently defined mineral resource, returning grades of up to 10.25 g/t Au over 0.50 m. Final assay results are still pending for 8 of the holes. Monarch holds a 100% interest in the Swanson property, which consists of one mining lease and 127 claims covering over 51.26 km2.

07:40 EDT In8bio appoints Michael Bishop to Scientific Advisory Board - IN8bio announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board. Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago.

07:38 EDT Emcor announces EFS awarded five-year contract with Siemens Energy - Emcor announced that Emcor Facilities Services, or EFS, a division of Emcor Building Services, and Emcor Group have been awarded a five-year contract with Siemens Energy. The contract spans 49 sites across the United States and Canada in North America and 30 sites across 10 countries in Europe, including 15 sites in the UK. In North America, the contract will be delivered through EFS, where over 100 employees will provide hard and soft services across the locations. In Europe, it will be delivered in partnership between Emcor UK and European Customer Synergy, or ECS, a pan-European FM services provider. Approximately 120 EMCOR UK employees will deliver a mix of hard and soft FM services.

07:36 EDT Williams acquires natural gas firm NorTex Midstream in $423M transaction - Williams announced that it has acquired NorTex Midstream, a fully contracted natural gas pipeline and storage asset located in north Texas, from an affiliate of Tailwater Capital. The $423M transaction, which closed on August 31 , includes approximately 80 miles of natural gas transmission pipelines and 36 Bcf of natural gas storage in the Dallas-Fort Worth market. The NorTex assets provide critical service to approximately 4 GW of gas fired power generation, enabling Texas energy providers to successfully meet peak demands. In addition to providing critical gas supply to power generation in north Texas, these assets also position Williams to provide storage services for Permian gas directed toward growing Gulf Coast LNG demand.

07:34 EDT Mind Medicine announces results on Phase II study of MM-120 - Mind Medicine announced that the manuscript "Lysergic Acid Diethylamide-Assisted Therapy In Patients With Anxiety With And Without A Life-Threatening Illness A Randomized, Double-Blind, Placebo-Controlled Phase II Study," has been published in the peer-reviewed scientific journal Biological Psychiatry. The paper expands on previously reported positive data that was featured in an oral presentation at the PSYCH Symposium in London on May 11, 2022. Rob Barrow, CEO and Director of MindMed, stated: "This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders. Acute administration of LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms for up to 16 weeks. These results are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD after just a single-dose administration. Patient dosing in our Phase 2b trial for MM-120 is ongoing and we are continuing to leverage this momentum in our mission to bring our novel therapeutic option to market. We believe MM-120 has a highly attractive commercial opportunity given its potential benefits for GAD patients. We also continue to advance our efforts to further strengthen the protection of our intellectual property and proprietary technology that is important to our business. Our exclusive rights to the data from this study through our strong and productive collaboration with the Liechti Lab at UHB only enhance our leading position in the development of MM-120. We continue to protect and build on this position by filing multiple layers of intellectual property applications and continue to retain clinical data, manufacturing rights to and know-how for our proprietary MM-120 product, which we believe offers significant advantages as a pharmaceutical product over the free-base form of LSD."

07:23 EDT Gamesquare Esports launches Mission Supply merchandise company - GameSquare Esports (GMSQF) announced that it has added the former VP Consumer Products at FaZe Clan (FAZE), Derek Chestnut, as Head of Consumer Products. The Company also announced the launch of Mission Supply Co to provide merchandise and consumer product design, marketing, and sales consultation to brands and esports organizations seeking to reach the large and growing gaming demographic. In addition, Mission Supply will develop, design, and create innovative designs for Complexity, Complexity Stars, and GameSquare's growing roster of influencers and content creators. Mission Supply launches with an established customer list, which includes leading esports companies, lifestyle brands, and e-commerce marketplaces. Chestnut has launched, built, and led merchandise businesses that grew to multi-million-dollar divisions, and he has led some of the most exciting collaborations in gaming with large globally recognizable brands including Disney, Takashi Murakami, Juice WRLD, and BEATS. Management expects Mission Supply to contribute to GameSquare's revenue in 2022.

07:20 EDT Idaho Strategic announces Klondike exploration drift update - Idaho Strategic Resources announces that it intercepted new mineralized veins along with reaching the targeted vein in its exploration drifting in the Klondike area at the Golden Chest. Drifting along the vein in the crosscut revealed a section of visible gold in a swarm of quartz veins, with a grab sample of a 10-centimeter solid pyrite vein that assayed 1,300 grams per tonne gold - the highest gold assay ever at the GC. The targeted vein was found approximately 60 meters from the existing workings. The drift passed through the trace of GC 21-207 previously reported and the grade and size of the vein were confirmed to be as reported.The new vein strikes nearly east-west and dips very shallowly to the north, a unique vein orientation not seen at the Golden Chest until now. A crosscut was driven to the south following the vein up-dip 30 meters to the Red Star Fault. A series of panel samples 1.5 meters in length and varying thickness were taken on both ribs by IDR geologists. A representative sample was taken of individual panels and included vein material and the host argillite-siltite rock within the panel.

07:19 EDT Altamira Therapeutics to participate in RAS-Targeted Drug Development Summit - Altamira Therapeutics announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts. The Company currently has two RNA-based development programs utilizing its patented OligoPhore delivery platform and proprietary siRNA formulated to target KRAS and NF-B signaling pathways. The first is the AM-401 program, which targets KRAS-driven cancers that commonly affect the pancreas, lungs, or colorectum. The second is AM-411 for the treatment for rheumatoid arthritis. Altamira's CSO, Samuel A. Wickline, MD, will be presenting on the topic titled, "Extrahepatic Nucleotide Delivery with Self-Assembling Peptide-Based Nanostructures for RNAi against KRAS" and discuss the Company's approach to treating KRAS-driven cancers and the key advantages of its OligoPhore delivery platform for targeting KRAS. Dr. Wickline will address the following aspects of siRNA therapeutics that differentiate the Company's technology: Formulation of therapeutic polyplexes by noncovalent self-assembly with any type of single or multiplexed RNAs that are stable and safe in circulation; Avoidance of hepatic uptake after systemic injection allowing accelerated permeation into tumor microenvironments and direct uptake by cancer cells; Rapid and extensive pH-dependent release of RNA from endosomal compartments resulting in early and potent control of pathological protein expression. Altamira aims to become a leading provider of facile peptide-based polyplex technologies for extrahepatic RNA delivery. It actively seeks opportunities to out-license its AM-401 and AM-411 nanoparticle technologies as well as its OligoPhore and SemaPhore delivery platforms to other biopharmaceutical companies.

07:16 EDT Electra Battery released highlights on study on EV battery materials facility - Electra Battery Materials released highlights of a scoping study prepared by a global engineering firm supporting the creation of an integrated electric vehicle battery materials park in Ontario that would include nickel, cobalt and manganese refining, recycling of battery black mass material, and precursor cathode active material manufacturing. The scoping study assessed the economics and carbon footprint of various nickel feed options to develop an integrated facility producing 10,000 tonnes per annum of battery grade nickel sulfate and nickel equivalent pCAM, components essential to production of electric vehicle batteries. "With U.S. electric vehicle manufacturers moving swiftly to reduce reliance on Chinese and Russian critical minerals in order to qualify for the $7,500 EV credit under the Inflation Reduction Act, Electra is capitalizing on the opportunity to provide secure domestic supply of EV battery materials," said Trent Mell, CEO of Electra Battery Materials. "The scoping study supports our view that an integrated refining-recycling-pCAM battery materials complex in Ontario would deliver compelling economics, emit low carbon emissions and address the onshoring of battery materials needed by the North American automotive industry." Mell added, "Backed by compelling project economics, we are now proceeding with an engineering prefeasibility study to narrow our focus on feed sources and devise a multi-phased approach to growing nickel refining capacity in North America."

07:16 EDT Amryt Pharma's Filsuvez approved in Great Britain for Epidermolysis Bullosa - Amryt announced that the Medical Healthcare & Products Regulatory Agency has granted Marketing Authorisation Approval and Orphan Disease Designation for Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa in patients 6 months and older in Great Britain, a rare and distressing genetic skin disorder affecting young children and adults. The global market opportunity for EB is estimated by the company to be in excess of $1.0B.

07:15 EDT Verisk Analytics launches new Industry Risk Analytics - Verisk Maplecroft has launched its new Industry Risk Analytics to provide companies, insurers and financial institutions with a new geospatial risk solution that identifies the exposure of 80 sectors to 52 different ESG and political risks across 198 countries. The data can be used to underpin and strengthen analysis of a wide range of risks impacting operations, supply chains and investments globally by offering in-depth insight into how country-level risks vary between industries.

07:14 EDT H-CYTE terminates LOI to acquire Catheter Precision - H-CYTE announced the termination of the previously announced letter of intent, whereby H-CYTE would acquire Catheter Precision. The Company has decided that it would rather focus its current and future capital on other leading biologics and bringing new technologies to market.

07:13 EDT Akoustis awarded two new design wins in gaming market - Akoustis has received two design wins for Wi-Fi 6E XBAW filter products for the gaming market. Both design wins are for products that are expected to go into production by mid-calendar 2023. One of the design wins is for a specialized gaming router, using a multiple-user-multiple-in-multiple-out architecture. The other design win is for an end-user gaming platform that will use Wi-Fi 6E connectivity to enhance data-throughput speed and provide lower latency than current generation products. Akoustis is currently ramping commercial production and is investing to achieve annual production capacity of approximately 500 million units. To date, Akoustis has received more than 20 customer design wins for its patented XBAW filter solutions.

07:12 EDT United Airlines invests another $15M in eVTOLs market with Eve - United (UAL) announced a $15M investment in Eve Air Mobility (EVEX) and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options, expecting the first deliveries as early as 2026. This marks another significant investment from United in flying taxis - or eVTOLs, electric vertical take-off and landing vehicle - that have the potential to revolutionize the commuter experience in cities around the world. Under the terms of the agreement, the companies intend to work on future projects, including studies on the development, use and application of Eve's aircraft and the urban air mobility, UAM, ecosystem. United signs purchase agreement for up to 400 eVTOL aircraft from Eve aiming to revolutionize commuter experience in cities around the world. "United has made early investments in several cutting-edge technologies at all levels of the supply chain, staking out our position as a leader in aviation sustainability and innovation," said Michael Leskinen, President of United Airlines Ventures. "Today, United is making history again, by becoming the first major airline to publicly invest in two eVTOL companies. Our agreement with Eve highlights our confidence in the urban air mobility market and serves as another important benchmark toward our goal of net zero carbon emissions by 2050 - without using traditional offsets. Together, we believe our suite of clean energy technologies will revolutionize air travel as we know it and serve as the catalyst for the aviation industry to move toward a sustainable future."

07:11 EDT Societal CDMO appoints Elena Cant to board of directors - Societal CDMO announced the appointment of Elena Cant to the company's board of directors. Ms. Cant currently serves as the COO at TwinStrand Biosciences, where she leads the company's operational organization in support of its efforts to develop its next-generation DNA sequencing technology.

07:10 EDT BBTV Holdings enters agreement with Harlem Globetrotters - BBTV Holdings announced it has entered into an agreement to provide comprehensive Content Management solutions to the World Famous Harlem Globetrotters, the originators of basketball style. As part of BBTV's expansive Content Management solutions, BBTV will provide the Harlem Globetrotters with Rights Management, Channel Management and Content Development solutions across multiple platforms. "The Harlem Globetrotters are truly iconic in the world of basketball, instilling in a global community of fans a true love for the game. That kind of inspiration is one of the keys to building and expanding a strong community for the digital generation," commented Lewis Ball, Chief Strategy Officer, BBTV. "We've seen first-hand how powerful sports fandom can be for Millennials and Gen Z across digital platforms, and we couldn't be more excited to harness that power for the Globetrotters. Working on a comprehensive basis really enables us to exercise the full power of our Content Management solutions, from Rights and Channel Management to Content Development. These solutions truly combine to be more than the sum of their parts, as they work together hand-in-hand to build a community that extends well-beyond any individual platform."

07:09 EDT Enthusiast Gaming entering strategic Web3 collaboration with Coinbase - Enthusiast Gaming (EGLX) announced a collaboration with Coinbase Global (COIN). The announcement introduces Coinbase as the preferred infrastructure provider to power Enthusiast Gaming's portfolio of Web3-enabled games. Coinbase will provide developer tools, educational content, and community-building support to power Enthusiast Gaming's portfolio of Web3-enabled games. The partnership centers around Enthusiast Gaming's EV.IO, a novel, browser-based, first-person shooter game, that allows users to earn cryptocurrency as rewards for in-game achievements.

07:08 EDT FDA approves Revance's Daxxify injection to improve facial frown lines - Revance Therapeutics announced that the United States Food and Drug Administration has approved DAXXIFY, DaxibotulinumtoxinA-lanm, for injection for the temporary improvement of moderate to severe frown lines in adults. DAXXIFY is the first and only neuromodulator stabilized with Peptide Exchange Technology PXT and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFY has the ability to address duration of treatment effect, which we believe is the greatest unmet need with existing neuromodulators for both consumers and injectors.12 The FDA approval, Revance's first, augments the company's innovative aesthetics portfolio and expands the company's access to the growing $3.2B U.S. facial injectables market, further establishing Revance as an innovation leader in the industry and laying the groundwork for potential future therapeutic indications.13

07:07 EDT Emerita Resources announces drill results at Iberia Belt West project - Emerita Resources announced that it continues to accelerate drilling at its wholly owned Iberia Belt West project. Presently there are 9 drills on the La Romanera deposit delineation and 1 rig continues to drill at Infanta. Assay results have been received from drill holes at the La Romanera deposit and the La Infanta deposit reported below. To date, 23 drill holes have been completed on the La Romanera deposit which is the main focus of the IBW program. According to Joaquin Merino, P.Geo., President of Emerita: "The additional drills will ensure the Company stays on track to meet our objectives with respect to delineating the La Romanera deposit. Restrictions on drilling between 2-8 PM, related to high temperatures and resulting forest fire index, are also expected to end by September 21 as temperatures moderate which will allow 24 hour operations to resume and boost productivity as well. Hunting season, which commences October 15, is not expected to impact the drill program at the La Romanera deposit."

07:07 EDT Churchill Downs enters into multi-year agreement with FanDuel - Churchill Downs announced a multi-year agreement with FanDuel involving multiple facets of FanDuel's sports wagering, advance deposit wagering and television businesses. Under the agreement, CDI will provide certain technology and services to enable FanDuel's customers to place pari-mutuel wagers on horse racing via FanDuel's sports wagering and ADW platforms. CDI will also authorize wagering on CDI's owned or controlled horse racing content via FanDuel's platforms in the U.S. and grant FanDuel certain television and media rights to broadcast CDI-owned racing content on FanDuel's television networks. In addition, the Agreement provides FanDuel non-exclusive Kentucky Derby sponsorship rights within the sports wagering category. Beginning in January 2023, FanDuel will pay for CDI technology and services provided by United Tote to facilitate pari-mutuel wagering on FanDuel's platforms in the U.S., including FanDuel Sportsbook and TVG. CDI has entered into an agreement to sell 49% of United Tote to New York Racing Association in a transaction that is expected to close by the end of 2022. FanDuel will also receive exclusive television rights to the racing content of all CDI thoroughbred racetracks, including Churchill Downs Racetrack, once its existing non-Derby media rights deal expires in 2023. FanDuel will also receive a non-exclusive sponsorship of the Kentucky Derby in the sports wagering category beginning in 2023 in exchange for an annual sponsorship fee.

07:06 EDT Microbot Medical appoints Sebastian Flacke to Scientific Advisory Board - Microbot Medical announced the newest appointment to its Scientific Advisory Board, Sebastian Flacke, M.D. Flacke, M.D. joined Lahey Clinic in Boston in 2007 as Chief of Interventional Radiology and Director of non-invasive Cardiovascular Imaging and has since greatly expanded the interventional and cardiovascular program.

07:04 EDT Neximmune, Selexis in pact to advance immunotherapies targeting rare cancers - Selexis, a JSR Life Sciences company, and NexImmune announced that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis' SUREtechnology Platform a suite of cell line development technologies that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines. The Selexis-generated cell lines will be used to manufacture HLA IgG4 fusion proteins and T cell co-stimulatory monoclonal antibodies that will be incorporated into NexImmune's proprietary AIM injectable nanoparticle modality. These nanoparticles are designed to be an off-the-shelf injectable modality to engage a patient's own T cells to identify and kill a variety of diseased cells within the body. "We are pleased

07:04 EDT MasterCraft Boat sells NauticStar to Iconic Marine Group - MasterCraft Boat Holdings announced that its NauticStar business was acquired by a subsidiary of Iconic Marine Group. Iconic Marine Group assumed substantially all liabilities related to the NauticStar business and intends to continue operating the NauticStar business as usual. The transaction, which closed on September 2, 2022, is subject to a customary working capital adjustment. As previously announced on August 9, 2022, the NauticStar business will be accounted for as discontinued operations under GAAP beginning in the Company's fiscal first quarter of 2023. Additional detail will be provided on the Company's fourth quarter and full year 2022 conference call on September 8, 2022.

06:57 EDT Amylyx to resume trading at 7:10 am ET - Amylyx will resume trading at 7:10 am ET, with quotation scheduled to resume at 7:05 am ET, according to Nasdaq. The shares were halted yesterday ahead of the company announcing that the FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 7 yes votes and 2 no votes that the available evidence of effectiveness is sufficient to support approval of AMX0035, also known as ursodoxicoltaurine, for the treatment of amyotrophic lateral sclerosis, or ALS.

06:53 EDT Endeavour Silver reports drill results from Parral project - Endeavour Silver reports drill results from its ongoing drill program at its Parral project in the State of Chihuahua, Mexico. The high-grade silver results show the potential for resource expansion at depth and along strike in the El Verde and Sierra Plata Deep areas along the Veta Colorada structure. Since April of this year, the Company has drilled over 5,300 meters in 23 holes, totaling 8,100 meters year to date, with the aim to define and extend mineralized zones. Considerable exploration potential remains along the 35 square kilometre land package and exploration will be on-going, with additional testing for new discoveries with surface mapping and sampling underway. This program will aid the Company's goal to define a mineral resource large enough to support a preliminary economic assessment. Highlights from Recent Drill Results: 199 gpt Ag, 4.68% Pb and 2.64% Zn for 428 gpt AgEq over a 3.48 m ETW, including 501 gpt Ag, 8.08% Pb and 6.50% Zn for 971 gpt AgEq over 0.27 m; 322 gpt Ag, 5.19% Pb and 1.62% Zn for 528 gpt AgEq over a 1.67 m ETW, including 605 gpt Ag, 14.8% Pb and 3.46% Zn for 1,150 gpt AgEq over 0.53 m; 664 gpt Ag, 1.88% Pb and 0.80% Zn for 747 gpt AgEq over a 5.56 m ETW, including 5,600 gpt Ag, 15.35% Pb and 1.75% Zn for 6,096 gpt AgEq over 0.22 m; 242 gpt Ag, 0.48% Pb and 1.66% Zn for 317 gpt AgEq over a 5.34 m ETW, including 711 gpt Ag, 0.53% Pb and 2.13% Zn for 806 gpt AgEq over 0.52 m. "In the areas of the El Verde and Sierra Plata historically mined areas, we continue to verify extensions of the mineralized zones at depth and along strike," stated Dan Dickson, Chief Executive Officer. "The focus for the rest of the year will be to test the northern part of the project with a surface drilling program on various north to south striking structures, such as the northern extension of Veta Colorada, San Alberto and the El Cabezon systems; as well as resuming drilling of the San Patricio vein."

06:50 EDT Northern Dynasty: PLP submits comments to EPA on veto of Pebble Project - Northern Dynasty Minerals announces that its 100%-owned U.S.-based subsidiary Pebble Limited Partnership has submitted extensive comments objecting to the Environmental Protection Agency's preemptive veto of the Pebble Project. The Pebble Partnership called upon the agency to withdraw its action and refrain from further action against the project, thus allowing the appeal process undertaken by the U.S. Army Corps of Engineers to conclude. PLP CEO John Shively had the following statement about the comments submitted by PLP: "The comments we filed today clearly show there is absolutely no justification for the EPA's actions against the Pebble Project. The EPA's proposed veto of Pebble is legally, environmentally and technically unsupported. The EPA action is premature and it flies in the face of decades of regulatory precedent for fair and due process for development projects in Alaska and in the nation. The EPA's actions are politically motivated, and in our comments today we spell out just how indefensible this veto process has become. The EPA has made wildly speculative claims about possible adverse impacts from Pebble's development that are not supported by any defensible data and are in direct contradiction with the facts demonstrated in the USACE's Final Environmental Impact Statement for the Pebble Project. The FEIS clearly states that Pebble can be developed without harm to the Bristol Bay fishery. Regulations and court precedent specify EPA must establish that development will have demonstrable adverse impacts before it can initiate a veto, and the EPA did not do this. Simply put, EPA's speculation about impacts is not the same as demonstrating impacts will occur. Congress did not give the EPA broad authority to act as it has in the Pebble case. The 404 veto was intended to be narrowly defined and for specific areas. In this case, the EPA has preemptively vetoed 309 square miles of state of Alaska land, an area 66 times larger than any previous 404 veto. In fact, this site prohibition is 23 times larger than the entire mine site footprint. This is clearly a massive regulatory overreach by the EPA and well outside what Congress intended for the agency when it passed the Clean Water Act. Perhaps the most egregious aspect of this entire process is the EPA's blatant dismissal of the significant economic benefits this project could have for the region and for the state without explanation or justification. The EPA gives short shrift to what hundreds, if not thousands, of jobs could mean for the communities around Iliamna Lake. I know from personal experience what jobs mean for Alaska's smaller, rural communities and for the Alaska Natives who live there. The Final EIS clearly demonstrates the dramatic impact responsible Pebble development could have for these communities. The benefits are indisputable. Should the EPA finalize its Pebble veto, there are numerous violations of rights, agreements and laws that profoundly affect the future of Alaska, and these will likely be contested in court. EPA has blatantly ignored the state of Alaska, which is the landowner that specifically selected the Pebble area for its mineral potential. If the EPA finalizes its veto and precludes any development on 309 square miles of Alaska land, it would be violating Alaska's Statehood Compact and the 'no-more' clause of the Alaska National Interest Lands Conservation Act, which requires congressional approval of any additional park land in Alaska. The EPA would also be violating the U.S. Constitution by taking away the State and the project's legally protected property interests in the mineral rights underlying the land, without any just compensation. EPA gives little to no consideration to the critical role copper will play in our nation's transition to more renewable sources of power. There are multiple studies and reports that point to a looming supply gap for copper in the decades ahead. Pebble could be a critical source for the copper the nation needs to make this transition, or the U.S. will face the reality of being dependent upon China for the copper and other minerals necessary for green energy. Thus, for numerous legal, environmental, technical and economic reasons, the EPA should withdraw its actions against Pebble and let the established permitting and review process function as designed. Our team has submitted a thorough and detailed set of comments against the EPA's preemptive veto of Pebble and I encourage all project stakeholders to read them."

06:47 EDT Land's End announces collection with Blake Shelton - Lands' End and Blake Shelton announce a fall and holiday collection - Blake Shelton x Lands' End. The collaboration will offer apparel for every member of the family as well as items for the home, grounding itself in familiarity. The Lands' End x Blake Shelton collection will feature men's, women's and kids' apparel, spanning stylish layers, show stopping denim and graphic tees, as well as pet essentials like beds and bandanas and cozy home finds, including faux fur throws, percale sheets and more.

06:41 EDT Wallbridge Mining to update Detour-Fenelon gold trend resource estimate - Wallbridge Mining has commissioned an update to the 2021 mineral resource estimate for its flagship Fenelon Gold and Martiniere project. In addition, the company has initiated a preliminary economic assessment of Fenelon. For Fenelon, the 2023 MRE will incorporate data from an additional 100,000 meters of drilling completed since the 2021 MRE, and will focus on optimizing the resource for a predominantly underground bulk mining operation. The 2023 MRE will also include an updated resource for Martiniere, situated 30 km west of Fenelon, where the company has completed an additional 30,000 meters of drilling since the 2021 MRE. The 2023 MRE, expected to be completed in 1Q23, will form the foundation for a PEA which will assess the potential for a predominantly underground bulk mining operation at Fenelon. The PEA is expected to be completed by end of 2Q23. Fenelon is located 75 kilometers east of the Detour Lake gold mine. Martiniere is located 30 kilometres west of Fenelon. Beyond these known gold resources, the company sees strong potential to make additional discoveries on its largeprospective Detour-Fenelon Gold Trend land package spanning 97 kilometers of strike length.

06:37 EDT Cazoo winding down EU business to focus on UK market - Cazoo proposes to wind down operations in mainland Europe to focus on core UK market EU withdrawal ensures business has a plan that removes requirement for further funding UK used car market largest in Europe with c.8m transactions worth over GBP 100bn annually Cazoo well-positioned to capture the enormous UK market opportunity over the long-term Focus on cash preservation and now expecting to reach Company breakeven by end 2023 Expected net savings of over GBP 100m by end of 2023 resulting from withdrawal from the EU Employee consultations to start immediately in each market with the relevant unions notified Record UK revenues and retail unit sales in August despite tough macro-economic backdrop Cazoo concluded the strategic review of its EU business with the aim of further preserving cash and positioning the company to achieve profitability without the need for further external capital. Management has concluded that the right course of action is for Cazoo to now focus exclusively on its core opportunity in the UK, with approximately 8 million used car transactions and a value of over GBP100B annually. Growth in the UK remains strong, with retail unit sales up over 100% year-on-year in July and August. The demand leaves management confident in Cazoo's ability to capture a 5% or greater UK market share. The plan to withdraw from the EU is based on the material further investment that would be required for Cazoo to continue to scale its operations in the EU. As a result, the company intends to commence an orderly wind down of its operations in Germany and Spain and is in consultation with its employee representatives in France and Italy. Cazoo will facilitate a structured closure for its customers, employees and suppliers and has notified the relevant employee representatives and unions in each market. It is expected that the company will achieve cash savings of over GBP100M, net of any wind down costs, as a result of its withdrawal from the EU, by the end of 2023. The company is now targeting cash flow breakeven by the end of 2023, at which point the company expects to still have approximately GBP100M of cash on its balance sheet. The EU businesses represented less than10% of company revenues and retail units in H1 2022 and the company believes this decision should have limited impact on its 2022 revenue and unit targets.

06:25 EDT Linde to build 35-megawatt PEM electrolyzer in New York - Linde announced that it will build a 35-megawatt PEM, or Proton Exchange Membrane, electrolyzer to produce green hydrogen in Niagara Falls, New York. The new plant will be the largest electrolyzer installed by Linde globally and will more than double Linde's green liquid hydrogen production capacity in the United States. Linde will build, own and operate the industrial-scale electrolyzer and use hydroelectric power to produce green liquid hydrogen. The plant is expected to start up by 2025. Linde will leverage its existing liquefier and distribution infrastructure to supply existing and new customers. This project is the first of several electrolyzers Linde expects to build in the U.S. to address green liquid hydrogen demand.

06:17 EDT Life Time Group opens Life Time One Wall Street - Life Time announced the opening of Life Time One Wall Street, the first of three athletic club destinations planned to open in New York City by the end of 2022. Located in the One Wall Street Development in the Financial District, the 74,000-square-foot destination covers four floors and features something for everyone from 90 days old to 90 years old.

06:10 EDT Equifax announces release of FICO Score 10 based on Equifax data - Equifax Canada (EFX), in partnership with FICO (FICO) announced the release of FICO Score 10 based on Equifax data. FICO Score 10 was developed to provide improved predictive analytics to help assess credit risk on all consumer lending products including mortgages, auto loans, credit cards, and personal loans.

06:06 EDT Cedar Fair reports record revenues through Labor Day - Cedar Fair reported that year-to-date preliminary net revenues through Monday, Sept. 5, 2022, totaled a record $1.37B, driven by record levels of in-park per capita spending - $61.11 - and out-of-park revenues - $163M -. Through Labor Day 2022, the company's 15 parks have entertained a total of 20.5 million guests. For the five-week period ended Sept. 5, 2022, the company entertained 5.1 million guests and generated preliminary net revenues of $343M, representing an increase of $74M, or 27%, when compared to the five-week period ended Sept. 9, 2019. Compared to the five-week period ended Sept. 6, 2021, net revenues in the recently ended five-week period were up 13%, or $40M, driven in large part by an increase of 15%, or 660,000 visits, in attendance. Over this same period, in-park per capita spending totaled $62.17, down 2% from comparable 2021 levels, and out-of-park revenues totaled $39M, up $7M, or 21%, from the same five-week period in 2021. On a per operating day basis, net revenues in the recently ended five-week period averaged approximately $740K, representing a 3% increase compared to the same five-week period last year. During the five-week period ended Sept. 5, 2022, average daily attendance increased 5% compared to the same period in 2021.

06:01 EDT ChipMOS reports August revenue $56.5M, down 28.5% - ChipMOS reported its unaudited consolidated revenue for the month of August. Revenue for the month of August was $56.5M, a decrease of 12% compared to July and a decrease of 28.5% compared to August 2021. The company noted that the sequential and year over year declines in its August revenue are consistent with the near-term demand and inventory adjustments impacting the broader semiconductor industry.

05:29 EDT AT&T reiterates expectations for improved cash conversion in 2023 - Pascal Desroches, senior executive vice president and chief financial officer, AT&T, spoke at the Bank of America Media, Communications and Entertainment Conference where he provided an update to shareholders. Desroches reiterated that AT&T continues to take a return-focused approach to growth and investment and made the following points: "The company continues to add customers in its strategic focus areas of 5G and fiber. Overall industry postpaid phone volumes remain healthy, and AT&T has continued to see solid demand with continued low postpaid phone churn. In addition, AT&T's consistent, disciplined and simple go-to-market approach continues to attract high-value customers. Desroches indicated that the impacts of recent pricing action on churn are within AT&T's expected range and the company continues to expect that the pricing changes will be accretive in the back half of the year. AT&T continues to expand its fiber footprint and has the ability to serve 18 million customer locations in more than 100 metro areas with AT&T Fiber. Desroches shared he's pleased with the increasing penetration rates for new fiber build. As AT&T expands to new markets, the company has seen first-year penetration rates about two times greater than historical norms. Desroches noted that AT&T is not seeing any material incremental shift in its cash collection cycles, which are within the company's expectations and largely consistent with normal pre-pandemic levels. While the current macroeconomic environment has reduced visibility into economic trends going into next year, Desroches reiterated expectations for improved cash conversion in 2023 compared to 2022. Factors driving the company's outlook for improved cash conversion include expectations for better service revenue levels exiting 2023 - from both a larger customer base and higher ARPUs - lower interest costs and the benefits from continued transformation savings. Expectations for improved cash conversion off this year's free cash flow guidance of the $14 billion range provide more than sufficient financial flexibility to meet AT&T's financial obligations - including its annual dividend commitment of $8 billion, or $1.11 per common share - even after factoring in the company's above historical capital investment levels."

05:24 EDT Teva announces results from two Ajovy studies - Teva announced the results of two studies presented at the Migraine Trust International Symposium, or MTIS, in London, UK, which demonstrate the efficacy of Ajovy in migraine patients who also experience depression or anxiety. Ajovy is indicated for the prevention of migraine in adults with at least four migraine days per month. In both studies, quarterly and monthly dosing of fremanezumab demonstrated efficacy in reducing monthly migraine attacks by more than 50% compared to placebo. This is an important outcome because psychiatric disorders are a common co-morbidity in patients suffering from migraine. Population-based samples of people with migraine show up to 47% have co-morbid depression, and up to 58% have co-morbid anxiety4 with many patients experiencing both psychiatric conditions. The first study is an analysis of pooled data from two previous six-month studies: HALO and FOCUS. The new study to be presented at MTIS sets out to analyze the efficacy of quarterly or monthly dosing of fremanezumab versus placebo in people with migraine and one or more psychiatric co-morbidities. Results at three months showed that 32% of patients on quarterly fremanezumab and 36% of patients on monthly fremanezumab achieved a greater than or equal to 50% reduction in monthly-migraine-days, or MMD, compared to 19% of those taking placebo and that proportion increased after continuing or switching to fremanezumab at month six. The second study is a sub-analysis of patients from the double-blind, placebo-controlled phase 3b FOCUS study led by Patricia Pozo-Rosich, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Research, Barcelona. The FOCUS study set out to evaluate the efficacy of quarterly or monthly fremanezumab in chronic or episodic migraine patients who had experienced an inadequate response to two to four classes of prior preventive migraine medication. The sub-analysis evaluated treatment efficacy on a sub-group of the migraine patients who had co-morbid depression. Reductions were observed in both monthly-migraine-days and monthly-headache-days with both quarterly and monthly fremanezumab compared with placebo. Differences were also seen in patient-reported depressive symptoms using a PHQ-9 questionnaire - a brief self-reporting instrument incorporating recognized depression criteria and other depressive symptoms suggesting that effective treatment of migraine can also positively impact depressive symptoms in patients with this co-morbidity. Details of enrolment progress into the UNITE study were also revealed at MTIS. The 28-week study, led by Richard Lipton and supported by Teva, will be assessing the efficacy and safety of fremanezumab in adult patients with chronic and episodic migraine and major depressive disorder.

05:15 EDT Alnylam announces APOLLO-B study meets primary endpoint - Alnylam announced results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated, or ATTR, amyloidosis with cardiomyopathy. The results were presented in a late-breaker session at the 18th International Symposium on Amyloidosis, or ISA. The company previously announced topline results from the APOLLO-B study in August. The 12-month study achieved its primary endpoint, with patisiran demonstrating a statistically significant and clinically meaningful benefit on functional capacity, as measured by the 6-Minute Walk Test, or 6-MWT, compared to placebo, with a median difference of 14.7 meters favoring patisiran. The study also met its first secondary endpoint, demonstrating a statistically significant and clinically meaningful benefit on health status and quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary, or KCCQ-OS, score, compared to placebo with least squares, or LS, mean difference of 3.7 points favoring patisiran. The study also included additional secondary composite outcomes endpoints. A non-significant result was found on the composite endpoint of all-cause mortality, frequency of cardiovascular events, and change from baseline in 6-MWT over 12 months compared to placebo. As a result, formal statistical testing was not performed on the final two composite endpoints. Patisiran also demonstrated an encouraging safety and tolerability profile in patients with ATTR amyloidosis with cardiomyopathy. APOLLO-B is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed and powered to evaluate the effects of patisiran on functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy. The study enrolled 360 adult patients with ATTR amyloidosis with cardiomyopathy at 69 sites in 21 countries. Patients were randomized 1:1 to receive 0.3 mg/kg of patisiran or placebo intravenously administered every three weeks over a 12-month treatment period. After 12 months, all patients will receive patisiran in an open-label extension. At 12 months, the study results presented are as follows: For 6-MWT, the median change from baseline to Month 12 was -8.15 meters for the patisiran group and -21.345 meters for the placebo group; the Hodges-Lehmann estimate of the median difference was 14.7 meters favoring patisiran. For KCCQ-OS, the LS mean change from baseline to Month 12 was +0.300 for the patisiran group and -3.408 for the placebo group, with an LS mean difference of 3.7 points favoring patisiran. Secondary composite outcome endpoints were tested in a hierarchical manner; however, the secondary composite outcomes endpoints did not achieve statistical significance. A non-significant result was found on the secondary composite endpoint of all-cause mortality, frequency of cardiovascular events, and change from baseline in 6-MWT over 12 months compared to placebo. The final two composite endpoints were not powered for statistical significance given the sample size and short duration of the study - all-cause mortality and frequency of all-cause hospitalizations and urgent heart failure visits in patients not on tafamidis at baseline and in the overall study population. Efficacy analysis of all-cause mortality excluded deaths due to COVID-19 and treated heart transplants in the same manner as deaths, as pre-specified in the statistical analysis plan. Per this definition, there were four deaths observed in patisiran-treated patients and 10 deaths observed in the placebo group. Patisiran achieved a rapid and sustained reduction in serum TTR levels, with a mean percent reduction from baseline in serum TTR reduction of 87% at Month 12. A beneficial effect on the exploratory endpoint, NT-proBNP, a measure of cardiac stress, was observed in the patisiran arm compared to placebo. The adjusted geometric mean fold change from baseline at Month 12 in NT-proBNP was 1.11 for the patisiran group and 1.38 for the placebo group, indicating a 20% reduction in the patisiran arm compared to placebo. Patisiran also demonstrated an encouraging safety and tolerability profile, including no cardiac safety concerns relative to placebo, during the 12-month treatment period. The majority of adverse events, or AEs, were mild or moderate in severity. Treatment emergent AEs occurring in 5% or more patients in the patisiran group and observed at least 3% more commonly than in the placebo group included infusion-related reactions, arthralgia and muscle spasms. In the safety analysis there were five deaths observed in patisiran-treated patients and eight deaths observed in the placebo group. Alnylam plans to file a supplemental new drug application, or sNDA, for patisiran as a potential treatment for ATTR amyloidosis with cardiomyopathy in the U.S. in late 2022. Additional results from the APOLLO-B study will be presented at the upcoming Heart Failure Society of America, or HFSA, annual meeting.

05:04 EDT Forge Global to expand private market platform into Europe - Forge Global announced its international expansion together with its strategic partner Deutsche Borse. Leveraging the technology and expertise of Forge, and market and regulatory know-how as well as the network of Deutsche Borse, Forge Europe will establish a digital marketplace for European companies and investors that provides access to Forge's U.S. liquidity network. Forge Europe will provide liquidity programs for companies, a marketplace that brings together buyers and sellers of private growth company shares and exclusive private market data that enable investors to make informed investment decisions.